MeSH term
Frequency | Condition_Probility | Albumins/metabolism | 4 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Humans | 2205 | 0.0 |
Animals | 468 | 0.0 |
Gene Expression | 32 | 0.0 |
Antilipemic Agents/*therapeutic use | 3 | 4.0 |
Clinical Trials | 2 | 0.0 |
Drug Combinations | 3 | 0.0 |
Apolipoproteins E/genetics | 206 | 64.0 |
Base Sequence | 108 | 0.0 |
DNA Primers/genetics | 6 | 0.0 |
Factor V/genetics | 2 | 2.0 |
Genotype | 857 | 8.0 |
Methylenetetrahydrofolate Reductase (NADPH2)/genetics | 2 | 4.0 |
*Mutation | 22 | 0.0 |
Peptidyl-Dipeptidase A/genetics | 9 | 11.0 |
Risk Factors | 372 | 6.0 |
Aged | 1000 | 3.0 |
Alleles | 556 | 7.0 |
Alzheimer Disease/*genetics/psychology | 7 | 100.0 |
Apolipoproteins E/*genetics | 830 | 92.0 |
*Cognition | 8 | 16.0 |
Female | 1162 | 1.0 |
Longitudinal Studies | 52 | 6.0 |
Male | 1249 | 1.0 |
*Memory | 2 | 12.0 |
Research Support, U.S. Gov't, P.H.S. | 784 | 1.0 |
Risk | 44 | 4.0 |
United States | 19 | 2.0 |
Aged, 80 and over | 483 | 4.0 |
Alzheimer Disease/blood/*genetics | 4 | 57.0 |
Apolipoproteins E/blood/*genetics | 59 | 88.0 |
DNA/genetics | 31 | 1.0 |
Gene Frequency | 296 | 6.0 |
*Polymorphism, Single Nucleotide | 15 | 2.0 |
Promoter Regions (Genetics)/genetics | 12 | 1.0 |
Research Support, Non-U.S. Gov't | 1436 | 1.0 |
Apolipoproteins C/*genetics | 23 | 25.0 |
Brazil | 5 | 2.0 |
Indians, South American/*genetics | 3 | 4.0 |
Linkage Disequilibrium | 23 | 2.0 |
Lipoprotein Lipase/*genetics | 6 | 3.0 |
*Multigene Family | 10 | 1.0 |
*Variation (Genetics) | 37 | 3.0 |
Alzheimer Disease/*genetics/metabolism/physiopathology | 8 | 61.0 |
Animals, Newborn | 7 | 1.0 |
Apolipoproteins E/genetics/*metabolism | 42 | 89.0 |
Cell Differentiation/*genetics | 2 | 2.0 |
Genetic Predisposition to Disease/genetics | 18 | 4.0 |
Heterozygote | 67 | 2.0 |
Mice | 282 | 0.0 |
Mice, Inbred C57BL | 82 | 2.0 |
Mice, Transgenic | 105 | 3.0 |
Neuronal Plasticity/*genetics | 3 | 42.0 |
Phenotype | 180 | 1.0 |
Protein Isoforms/genetics/metabolism | 6 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 103 | 1.0 |
Adult | 549 | 0.0 |
Case-Control Studies | 156 | 3.0 |
Dementia/*genetics | 21 | 61.0 |
European Continental Ancestry Group | 15 | 2.0 |
France | 9 | 3.0 |
Middle Aged | 836 | 1.0 |
Aging/metabolism | 8 | 5.0 |
Blood Flow Velocity | 2 | 2.0 |
Disease Models, Animal | 43 | 1.0 |
*Genetic Predisposition to Disease | 46 | 4.0 |
Gliosis/pathology | 2 | 11.0 |
Immunohistochemistry | 104 | 0.0 |
Magnetic Resonance Imaging | 35 | 3.0 |
Mice, Knockout | 82 | 3.0 |
Microglia/pathology | 2 | 20.0 |
Family Health | 15 | 1.0 |
*Lod Score | 3 | 8.0 |
Alzheimer Disease/*epidemiology/*genetics | 21 | 84.0 |
Cohort Studies | 78 | 3.0 |
Genetic Predisposition to Disease | 118 | 5.0 |
Promoter Regions (Genetics)/*genetics | 19 | 2.0 |
Age of Onset | 209 | 16.0 |
Alzheimer Disease/*genetics | 210 | 64.0 |
Comparative Study | 306 | 1.0 |
*Polymorphism, Genetic | 220 | 4.0 |
*Promoter Regions (Genetics) | 15 | 0.0 |
Calcium/*metabolism | 2 | 0.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
Gene Expression/drug effects | 2 | 0.0 |
Golgi Apparatus/metabolism | 2 | 1.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Intracellular Fluid/metabolism | 3 | 2.0 |
*Oxidative Stress | 3 | 1.0 |
Potassium Chloride/pharmacology | 2 | 3.0 |
Protein Transport | 2 | 0.0 |
Time Factors | 69 | 0.0 |
Tumor Cells, Cultured | 43 | 0.0 |
Greece/epidemiology | 5 | 14.0 |
Apolipoproteins B/*blood | 11 | 6.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Hyperlipidemia/*blood | 6 | 15.0 |
Postprandial Period/*physiology | 3 | 9.0 |
Triglycerides/*blood | 11 | 3.0 |
Genetic Markers | 39 | 1.0 |
Polymerase Chain Reaction | 114 | 0.0 |
Schizophrenia/*genetics | 8 | 3.0 |
Analysis of Variance | 70 | 3.0 |
Chi-Square Distribution | 42 | 5.0 |
Lipids/*blood | 70 | 12.0 |
Lipoproteins/*blood | 51 | 8.0 |
Lipoproteins, LDL/blood | 17 | 7.0 |
Body Composition | 3 | 1.0 |
Body Weight | 4 | 0.0 |
Cholesterol/blood | 106 | 8.0 |
*Diet | 12 | 5.0 |
Dietary Fats | 5 | 13.0 |
Energy Intake | 5 | 2.0 |
European Continental Ancestry Group/genetics | 21 | 3.0 |
Lipoproteins, HDL Cholesterol/*blood | 15 | 6.0 |
Lipoproteins, LDL Cholesterol/blood | 62 | 11.0 |
Regression Analysis | 44 | 2.0 |
*African Continental Ancestry Group | 3 | 2.0 |
Catchment Area (Health) | 4 | 22.0 |
Cognition Disorders/diagnosis/ethnology/*genetics | 2 | 100.0 |
Florida/epidemiology | 3 | 30.0 |
Neuropsychological Tests | 62 | 23.0 |
Polymorphism, Genetic/genetics | 35 | 5.0 |
Residence Characteristics | 4 | 21.0 |
Severity of Illness Index | 33 | 2.0 |
Alzheimer Disease/*genetics/metabolism | 17 | 53.0 |
Apolipoproteins E/*genetics/metabolism | 59 | 93.0 |
Chronic Disease | 3 | 0.0 |
Cross-Sectional Studies | 46 | 3.0 |
*Homozygote | 5 | 3.0 |
Memory Disorders/diagnosis/*etiology | 2 | 66.0 |
Cells, Cultured | 117 | 0.0 |
DNA Primers | 34 | 0.0 |
Glucose/*metabolism | 6 | 3.0 |
Heparitin Sulfate/*metabolism | 3 | 10.0 |
*Membrane Proteins | 11 | 1.0 |
Mutagenesis, Site-Directed | 13 | 0.0 |
Protein Binding | 63 | 0.0 |
Receptors, Immunologic/*metabolism | 8 | 4.0 |
Receptors, LDL/*metabolism | 23 | 25.0 |
*Receptors, Lipoprotein | 11 | 8.0 |
Recombinant Proteins/metabolism | 14 | 0.0 |
Apolipoproteins E/genetics/*physiology | 21 | 84.0 |
Variation (Genetics)/genetics | 6 | 3.0 |
Alzheimer Disease/*metabolism | 33 | 16.0 |
Apolipoproteins E/*metabolism | 95 | 87.0 |
Cholesterol/metabolism | 30 | 10.0 |
Lipids/metabolism | 22 | 6.0 |
Dementia/*genetics/*physiopathology | 2 | 100.0 |
Confidence Intervals | 17 | 5.0 |
Haplotypes/*genetics | 8 | 4.0 |
Multivariate Analysis | 21 | 1.0 |
Odds Ratio | 74 | 7.0 |
tau Proteins/*genetics | 10 | 52.0 |
Adolescent | 133 | 0.0 |
Apolipoproteins E/*biosynthesis | 6 | 100.0 |
Autopsy | 16 | 8.0 |
Brain/metabolism | 25 | 3.0 |
In Vitro | 29 | 0.0 |
Alzheimer Disease/etiology/*genetics | 10 | 90.0 |
Amyloid beta-Protein Precursor/*genetics | 17 | 27.0 |
Cathepsin D/genetics | 2 | 40.0 |
Membrane Proteins/*genetics | 32 | 3.0 |
Oxidative Stress/*genetics | 4 | 15.0 |
Polymorphism, Genetic | 177 | 3.0 |
Apolipoproteins E/*genetics/*metabolism | 19 | 95.0 |
Cholesterol, Dietary/*administration & dosage | 4 | 36.0 |
Dietary Fats/*administration & dosage | 6 | 7.0 |
Genes/*physiology | 2 | 16.0 |
Genome | 4 | 1.0 |
Linkage (Genetics) | 37 | 1.0 |
Multifactorial Inheritance | 2 | 16.0 |
Papio | 4 | 2.0 |
Particle Size | 27 | 9.0 |
Quantitative Trait, Heritable | 4 | 7.0 |
Age Factors | 100 | 4.0 |
Amyloid beta-Protein/genetics/*metabolism | 7 | 63.0 |
Cell Count | 8 | 0.0 |
Senile Plaques/genetics/pathology | 2 | 100.0 |
Sex Factors | 62 | 4.0 |
Chromosomes, Human, Pair 10/genetics | 4 | 5.0 |
*Genetic Markers | 9 | 2.0 |
Germany/epidemiology | 5 | 4.0 |
Hyperlipidemia/epidemiology/*genetics | 2 | 40.0 |
Lipids/*metabolism | 14 | 6.0 |
Variation (Genetics) | 34 | 2.0 |
Child | 92 | 0.0 |
Child, Preschool | 48 | 0.0 |
Infant | 32 | 0.0 |
Prognosis | 31 | 0.0 |
Reference Values | 100 | 2.0 |
Astrocytes/*metabolism | 8 | 12.0 |
Protein Isoforms/*metabolism | 5 | 20.0 |
Alzheimer Disease/epidemiology/*genetics | 38 | 65.0 |
Asian Continental Ancestry Group/genetics | 7 | 2.0 |
Genetic Screening | 27 | 3.0 |
Introns/*genetics | 6 | 3.0 |
Logistic Models | 39 | 5.0 |
RNA, Messenger/biosynthesis | 10 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 6 | 1.0 |
Steroid Hydroxylases/*genetics | 3 | 3.0 |
Aorta/metabolism/pathology | 5 | 35.0 |
Arteriosclerosis/genetics/*metabolism | 2 | 50.0 |
Diet | 11 | 3.0 |
Fibroblasts/cytology/metabolism | 4 | 2.0 |
Lipids/blood | 51 | 8.0 |
Lipoproteins/blood | 39 | 9.0 |
Receptors, LDL/genetics/*metabolism | 4 | 15.0 |
*Alcohol Drinking | 2 | 8.0 |
Health Surveys | 4 | 5.0 |
Magnetic Resonance Imaging/*methods | 2 | 2.0 |
Alzheimer Disease/enzymology/*genetics | 3 | 30.0 |
Exons/genetics | 10 | 0.0 |
Jews/*genetics | 2 | 1.0 |
Mutation | 52 | 0.0 |
Polymorphism, Single Nucleotide | 10 | 1.0 |
Mutation, Missense/genetics | 2 | 1.0 |
Pedigree | 52 | 0.0 |
Amino Acid Sequence | 74 | 0.0 |
Apolipoproteins E/*chemistry/metabolism | 7 | 77.0 |
Ligands | 9 | 0.0 |
Lipoproteins, LDL/metabolism | 17 | 7.0 |
Magnetic Resonance Spectroscopy | 5 | 0.0 |
Models, Molecular | 10 | 0.0 |
Molecular Sequence Data | 128 | 0.0 |
Protein Conformation | 27 | 0.0 |
Protein Structure, Secondary | 13 | 1.0 |
Receptors, LDL/metabolism | 22 | 22.0 |
Trifluoroethanol/pharmacology | 2 | 40.0 |
Alzheimer Disease/etiology/*metabolism | 3 | 42.0 |
Crosses, Genetic | 6 | 0.0 |
Homozygote | 56 | 2.0 |
Macrophages/metabolism | 9 | 2.0 |
Microglia/metabolism | 3 | 13.0 |
Nitric Oxide/*metabolism | 2 | 1.0 |
Protein Isoforms | 13 | 1.0 |
Apolipoproteins E/genetics/metabolism | 18 | 72.0 |
Carrier Proteins/genetics/metabolism | 2 | 1.0 |
*Glycoproteins | 11 | 1.0 |
*Haplotypes | 6 | 2.0 |
Lipoprotein Lipase/genetics/metabolism | 2 | 20.0 |
Lipoproteins, HDL/blood/*metabolism | 3 | 27.0 |
Receptors, LDL/genetics/metabolism | 3 | 14.0 |
Structure-Activity Relationship | 8 | 0.0 |
Alcohol Drinking | 5 | 3.0 |
Apolipoproteins/genetics | 5 | 21.0 |
Dietary Fats/administration & dosage | 6 | 6.0 |
Lipids/*blood/*genetics | 2 | 100.0 |
Cognition Disorders/*genetics/*physiopathology | 3 | 100.0 |
Educational Status | 11 | 16.0 |
Mental Status Schedule | 18 | 62.0 |
Apolipoproteins/blood | 16 | 7.0 |
English Abstract | 73 | 0.0 |
*Polymorphism, Restriction Fragment Length | 9 | 1.0 |
Triglycerides/blood | 101 | 7.0 |
Epistasis, Genetic | 2 | 3.0 |
Lod Score | 19 | 1.0 |
Models, Genetic | 19 | 1.0 |
Alzheimer Disease/metabolism | 6 | 9.0 |
Arginine/chemistry | 2 | 3.0 |
Cysteine/chemistry | 2 | 1.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Macromolecular Substances | 6 | 0.0 |
Protein Structure, Tertiary | 16 | 0.0 |
Alzheimer Disease/*blood | 3 | 21.0 |
Estradiol/*blood | 2 | 1.0 |
Folic Acid/*blood | 2 | 2.0 |
DNA Mutational Analysis | 35 | 0.0 |
Gene Frequency/*genetics | 9 | 6.0 |
Polymorphism, Genetic/*genetics | 94 | 7.0 |
Pregnancy | 17 | 0.0 |
Cholinesterase Inhibitors/*therapeutic use | 5 | 31.0 |
Indans/*therapeutic use | 2 | 50.0 |
Piperidines/*therapeutic use | 2 | 22.0 |
*Body Mass Index | 2 | 2.0 |
Lipids/blood/*metabolism | 3 | 16.0 |
Quebec | 3 | 5.0 |
Linear Models | 13 | 2.0 |
Aged, 80 and over/*physiology | 4 | 57.0 |
Memory/*physiology | 11 | 17.0 |
Verbal Learning/physiology | 3 | 50.0 |
Alzheimer Disease/*diagnosis | 2 | 25.0 |
Cognition Disorders/*diagnosis | 3 | 37.0 |
Follow-Up Studies | 54 | 1.0 |
*Neuropsychological Tests | 3 | 9.0 |
Predictive Value of Tests | 45 | 2.0 |
ROC Curve | 3 | 1.0 |
Reproducibility of Results | 10 | 0.0 |
Risk Assessment | 18 | 2.0 |
Glycoproteins/*genetics | 3 | 1.0 |
Polymorphism, Single Nucleotide/*genetics | 9 | 3.0 |
Codon/genetics | 6 | 1.0 |
HLA-DR Antigens/genetics | 2 | 0.0 |
Multiple Sclerosis/*genetics | 4 | 4.0 |
Apolipoproteins/analysis | 4 | 14.0 |
Apolipoproteins B/analysis | 3 | 10.0 |
Lipoproteins/*blood/chemistry | 4 | 33.0 |
Apolipoproteins E/*blood/genetics | 17 | 85.0 |
Blood Pressure | 9 | 1.0 |
Comorbidity | 12 | 4.0 |
Lipoproteins, HDL Cholesterol/blood | 58 | 8.0 |
National Institutes of Health (U.S.) | 3 | 12.0 |
Prevalence | 33 | 2.0 |
Protein Isoforms/blood | 3 | 13.0 |
Smoking/epidemiology | 3 | 4.0 |
Coronary Angiography | 7 | 3.0 |
Linkage Disequilibrium/genetics | 11 | 7.0 |
Membrane Glycoproteins/*genetics | 3 | 0.0 |
Brain/*metabolism/physiopathology | 5 | 29.0 |
Brain Chemistry/*genetics | 8 | 18.0 |
Models, Statistical | 11 | 5.0 |
Statistics | 9 | 1.0 |
Blotting, Western | 45 | 0.0 |
*Cell Death | 2 | 4.0 |
Cell Line | 68 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 54 | 1.0 |
Lipoproteins, VLDL/*metabolism | 15 | 21.0 |
Neurons/enzymology/*metabolism | 2 | 13.0 |
Phosphorylation | 14 | 0.0 |
Rats | 75 | 0.0 |
Apolipoproteins/blood/genetics | 2 | 40.0 |
Apolipoproteins E/*blood/*genetics | 13 | 92.0 |
Lipoproteins/*blood/genetics | 4 | 44.0 |
Cognition/physiology | 5 | 15.0 |
Apolipoproteins A/*genetics | 8 | 17.0 |
Carrier Proteins/*genetics | 5 | 0.0 |
Lipoproteins, HDL/blood | 21 | 8.0 |
*Phytosterols | 2 | 40.0 |
Receptors, Immunologic/*genetics | 9 | 7.0 |
Alzheimer Disease/genetics/*metabolism | 15 | 53.0 |
Amyloid beta-Protein Precursor/genetics | 22 | 44.0 |
*Disease Models, Animal | 3 | 0.0 |
Hippocampus/metabolism/pathology | 5 | 17.0 |
Protein Isoforms/genetics/physiology | 3 | 13.0 |
Senile Plaques/genetics/*metabolism/pathology | 2 | 100.0 |
Brain Chemistry | 11 | 4.0 |
Biological Markers/blood | 10 | 0.0 |
Disease Progression | 52 | 1.0 |
Proportional Hazards Models | 19 | 2.0 |
Prospective Studies | 60 | 1.0 |
Alzheimer Disease/*genetics/*mortality | 4 | 100.0 |
Neuropsychological Tests/statistics & numerical data | 4 | 22.0 |
African Continental Ancestry Group/*genetics | 9 | 3.0 |
Age Distribution | 18 | 5.0 |
United States/epidemiology | 9 | 2.0 |
Asian Continental Ancestry Group | 8 | 2.0 |
China | 13 | 2.0 |
Cholesterol/*blood | 26 | 10.0 |
Ethnic Groups | 2 | 0.0 |
Alzheimer Disease/*genetics/pathology | 19 | 59.0 |
Psychotic Disorders/*genetics/pathology | 2 | 100.0 |
alpha 1-Antichymotrypsin/*genetics | 27 | 84.0 |
Coronary Disease/*genetics | 8 | 13.0 |
Enzyme-Linked Immunosorbent Assay | 32 | 0.0 |
Taiwan/epidemiology | 3 | 2.0 |
*Gene Frequency | 26 | 4.0 |
Amyloid beta-Protein/*genetics/*metabolism | 4 | 66.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Oxidative Stress/drug effects/*genetics | 2 | 66.0 |
DNA Transposable Elements | 2 | 1.0 |
Gene Deletion | 15 | 0.0 |
Solubility | 9 | 0.0 |
Asia | 3 | 4.0 |
Dementia/*genetics/pathology | 3 | 50.0 |
Diabetes Mellitus, Type 2/*genetics | 3 | 1.0 |
Blood Glucose/*metabolism | 6 | 2.0 |
Cognition/*physiology | 15 | 21.0 |
Glucose Tolerance Test | 4 | 0.0 |
Amino Acid Substitution | 8 | 0.0 |
Exons | 27 | 0.0 |
Hungary | 5 | 9.0 |
alpha-Macroglobulins/*genetics | 18 | 36.0 |
Genetics, Population | 22 | 5.0 |
Italy/epidemiology | 6 | 2.0 |
Cerebrovascular Circulation | 2 | 3.0 |
Cognition Disorders/*genetics | 8 | 57.0 |
Memory Disorders/genetics | 2 | 66.0 |
Apolipoproteins C/*genetics/physiology | 2 | 66.0 |
Spain/epidemiology | 4 | 2.0 |
Apolipoproteins E/metabolism/*physiology | 4 | 100.0 |
Arteriosclerosis/metabolism | 7 | 11.0 |
Biological Transport/physiology | 4 | 2.0 |
Phospholipids/metabolism | 6 | 3.0 |
*Receptors, Immunologic | 5 | 3.0 |
Transfection | 31 | 0.0 |
Cardiovascular Diseases/blood/*genetics | 3 | 25.0 |
Environmental Exposure | 2 | 1.0 |
Pharmacogenetics | 4 | 3.0 |
Alzheimer Disease/*genetics/*physiopathology | 5 | 62.0 |
Cell Division | 9 | 0.0 |
Interleukin-1/*genetics | 4 | 4.0 |
Proteoglycans/*biosynthesis | 2 | 16.0 |
Receptors, LDL/genetics | 9 | 12.0 |
Alzheimer Disease/diagnosis/ethnology/*genetics | 2 | 100.0 |
European Continental Ancestry Group/*genetics | 13 | 3.0 |
Florida | 2 | 16.0 |
Heterozygote Detection | 17 | 3.0 |
Hispanic Americans/*genetics | 2 | 10.0 |
Alanine/genetics | 3 | 2.0 |
Alzheimer Disease/diagnosis/*genetics | 18 | 78.0 |
Amino Acid Substitution/genetics | 4 | 1.0 |
Base Pairing | 2 | 3.0 |
DNA, Mitochondrial/*genetics | 3 | 2.0 |
RNA, Transfer, Glu/genetics | 2 | 100.0 |
Threonine/genetics | 3 | 4.0 |
Variation (Genetics)/*genetics | 6 | 2.0 |
*Estrogen Replacement Therapy | 6 | 5.0 |
Apolipoproteins E/blood | 19 | 40.0 |
Bezafibrate/*therapeutic use | 2 | 14.0 |
Electrophoresis, Agar Gel | 8 | 1.0 |
Lipoproteins, LDL/*blood | 6 | 3.0 |
Chromosome Mapping | 35 | 0.0 |
Chromosomes, Human, Pair 1/genetics | 2 | 1.0 |
Chromosomes, Human, Pair 6/genetics | 2 | 1.0 |
Genetic Predisposition to Disease/*genetics | 21 | 5.0 |
Biological Transport, Active/drug effects | 3 | 5.0 |
Chloroquine/pharmacology | 2 | 2.0 |
Chylomicrons/metabolism | 4 | 17.0 |
Heparin/pharmacology | 3 | 1.0 |
Heparin Lyase/pharmacology | 2 | 15.0 |
Lipoproteins/*metabolism | 16 | 10.0 |
Lipoproteins, VLDL/metabolism | 18 | 17.0 |
Dementia/etiology/*genetics | 4 | 100.0 |
Survival Analysis | 18 | 0.0 |
Apolipoproteins E/deficiency/*genetics | 5 | 100.0 |
Electrocardiography | 2 | 0.0 |
Organ Size | 5 | 2.0 |
Survival Rate | 11 | 0.0 |
Asian Continental Ancestry Group/*genetics | 15 | 4.0 |
China/epidemiology | 6 | 3.0 |
Mutation/*genetics | 5 | 0.0 |
Adenoviridae/genetics | 13 | 2.0 |
Kidney Diseases/*genetics/metabolism | 2 | 66.0 |
*Point Mutation | 17 | 1.0 |
Transduction, Genetic | 7 | 1.0 |
Antibodies/blood | 2 | 3.0 |
Aorta/pathology | 4 | 10.0 |
Apolipoproteins E/analysis/*genetics/immunology | 2 | 100.0 |
Blotting, Western/methods | 3 | 1.0 |
Enzyme-Linked Immunosorbent Assay/methods | 5 | 1.0 |
Gene Therapy/*methods | 5 | 1.0 |
Genetic Vectors/*administration & dosage | 3 | 12.0 |
Transgenes | 5 | 1.0 |
Aging/*genetics/metabolism | 2 | 50.0 |
Neurofibrillary Tangles/genetics/pathology | 2 | 33.0 |
Amyloid beta-Protein/*metabolism | 49 | 53.0 |
Apolipoproteins E/*pharmacology | 21 | 91.0 |
Endocytosis/*drug effects | 2 | 9.0 |
Flow Cytometry | 3 | 0.0 |
Protein Isoforms/pharmacology | 5 | 25.0 |
Polymorphism, Genetic/physiology | 2 | 7.0 |
Receptors, LDL/*genetics | 17 | 10.0 |
Aorta/metabolism | 3 | 7.0 |
Arteriosclerosis/*metabolism | 10 | 15.0 |
Foam Cells/physiology | 2 | 50.0 |
In Situ Hybridization | 12 | 0.0 |
Muscle, Smooth/cytology | 2 | 8.0 |
RNA/metabolism | 3 | 0.0 |
RNA, Messenger/metabolism | 23 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 23 | 0.0 |
Transcription, Genetic | 16 | 0.0 |
Apolipoprotein A-I/blood | 8 | 7.0 |
Lipids/*blood/genetics | 2 | 25.0 |
Obesity/*genetics | 3 | 2.0 |
Cell Differentiation/drug effects | 3 | 0.0 |
Cell Division/drug effects | 5 | 0.0 |
Lipoproteins, HDL/*pharmacology | 3 | 21.0 |
Lipoproteins, LDL/*pharmacology | 2 | 3.0 |
Amyloid beta-Protein/analysis | 8 | 57.0 |
Apolipoproteins E/analysis | 7 | 43.0 |
Biopsy | 4 | 0.0 |
Cholesterol/*analysis | 2 | 20.0 |
Microscopy, Immunoelectron | 5 | 0.0 |
Receptors, LDL/analysis | 3 | 27.0 |
Receptors, Lipoprotein/*analysis | 2 | 100.0 |
Haplotypes/genetics | 7 | 1.0 |
Polymorphism, Single Nucleotide/genetics | 3 | 1.0 |
Probability | 8 | 1.0 |
Apolipoproteins E/chemistry/*metabolism | 12 | 92.0 |
Isoelectric Focusing | 31 | 5.0 |
Triglycerides/*metabolism | 6 | 7.0 |
Cholesterol/*metabolism | 28 | 10.0 |
Culture Techniques | 4 | 0.0 |
Foam Cells/drug effects/*metabolism | 2 | 100.0 |
Lipoproteins, HDL/pharmacology | 6 | 40.0 |
Macrophages/drug effects/*metabolism | 4 | 6.0 |
Chromosomes, Human, Pair 12/genetics | 4 | 4.0 |
Linkage (Genetics)/*genetics | 2 | 0.0 |
Sex Distribution | 22 | 8.0 |
Smoking/*adverse effects | 6 | 2.0 |
Alzheimer Disease/pathology | 7 | 31.0 |
Amyloid/*metabolism | 6 | 11.0 |
Apolipoproteins E/deficiency/genetics/*metabolism | 5 | 71.0 |
Alzheimer Disease/*ethnology/*genetics | 2 | 50.0 |
Caribbean Region/ethnology | 4 | 36.0 |
*Alleles | 113 | 8.0 |
Recurrence | 8 | 0.0 |
Haplotypes | 27 | 1.0 |
Spain | 10 | 2.0 |
*Age of Onset | 6 | 26.0 |
Chromosome Mapping/*methods | 3 | 1.0 |
Diagnosis, Differential | 15 | 0.0 |
Incidence | 31 | 2.0 |
Mass Screening | 3 | 1.0 |
Questionnaires | 10 | 1.0 |
Utah/epidemiology | 2 | 25.0 |
Amine Oxidoreductases/*genetics | 4 | 1.0 |
Aryldialkylphosphatase | 9 | 4.0 |
Cardiovascular Diseases/*genetics | 2 | 10.0 |
Esterases/*genetics | 4 | 5.0 |
Methylenetetrahydrofolate Reductase (NADPH2) | 8 | 1.0 |
Amyloid beta-Protein/*cerebrospinal fluid | 13 | 81.0 |
Apolipoproteins E/*cerebrospinal fluid/genetics | 4 | 80.0 |
Peptide Fragments/*cerebrospinal fluid | 9 | 81.0 |
Alzheimer Disease/epidemiology/etiology/*genetics | 3 | 100.0 |
*Amino Acid Substitution | 4 | 4.0 |
Apolipoproteins E/*genetics/physiology | 9 | 100.0 |
Multigene Family | 3 | 0.0 |
*Gene Targeting | 3 | 9.0 |
*Genetic Vectors | 4 | 1.0 |
Butyrylcholinesterase/*genetics | 9 | 33.0 |
Chromosomes, Human, Pair 3/*genetics | 2 | 0.0 |
Hypercholesterolemia/genetics | 3 | 37.0 |
RNA, Messenger/genetics | 13 | 0.0 |
Apolipoproteins E/*blood/classification/genetics | 2 | 100.0 |
Finland | 11 | 4.0 |
New York/epidemiology | 2 | 10.0 |
African Continental Ancestry Group/genetics | 10 | 3.0 |
Dementia/*epidemiology | 2 | 100.0 |
Likelihood Functions | 8 | 4.0 |
Cause of Death | 7 | 3.0 |
Activities of Daily Living | 3 | 8.0 |
Algorithms | 5 | 1.0 |
Lipoproteins, HDL Cholesterol/*metabolism | 4 | 11.0 |
Lipoproteins, LDL Cholesterol/*metabolism | 4 | 20.0 |
Sex Characteristics | 35 | 6.0 |
Switzerland | 2 | 2.0 |
Alzheimer Disease/*epidemiology/*genetics/pathology | 2 | 100.0 |
Retrospective Studies | 24 | 0.0 |
Polymorphism, Restriction Fragment Length | 44 | 1.0 |
Genetic Counseling | 3 | 1.0 |
Aging/physiology | 7 | 4.0 |
Apolipoproteins E/metabolism | 29 | 46.0 |
Brain/blood supply/*metabolism/pathology | 2 | 100.0 |
Estrogen Receptor alpha | 3 | 1.0 |
Point Mutation | 17 | 0.0 |
Receptors, Estrogen/genetics | 2 | 3.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Apolipoproteins E/*deficiency/*genetics/metabolism | 3 | 100.0 |
DNA Primers/chemistry | 5 | 0.0 |
Gene Transfer Techniques | 15 | 2.0 |
Genetic Vectors | 13 | 0.0 |
Mice, Mutant Strains | 13 | 1.0 |
Apolipoproteins B/blood | 28 | 11.0 |
Aging/*physiology | 16 | 5.0 |
Cognition Disorders/*epidemiology | 2 | 100.0 |
Reaction Time | 4 | 3.0 |
Alzheimer Disease/genetics/*pathology | 5 | 55.0 |
Brain/*pathology/physiopathology | 2 | 40.0 |
Neurons/pathology | 10 | 9.0 |
Alzheimer Disease/*metabolism/psychology | 3 | 60.0 |
Serum Amyloid A Protein/*metabolism | 4 | 10.0 |
alpha 1-Antichymotrypsin/*metabolism | 2 | 50.0 |
Korea | 8 | 3.0 |
Schizophrenia/*epidemiology/*genetics | 2 | 50.0 |
Aldehydes/metabolism | 2 | 16.0 |
Alzheimer Disease/genetics/*metabolism/physiopathology | 2 | 66.0 |
Amyloid beta-Protein/metabolism/*pharmacology | 3 | 50.0 |
Nerve Tissue Proteins/metabolism | 3 | 1.0 |
Neurons/*metabolism/pathology | 6 | 10.0 |
Peptide Fragments/metabolism/*pharmacology | 3 | 16.0 |
Reactive Oxygen Species/metabolism | 3 | 0.0 |
Alzheimer Disease/metabolism/pathology/physiopathology | 2 | 100.0 |
Antibodies, Monoclonal/diagnostic use | 5 | 0.0 |
Base Sequence/genetics | 3 | 0.0 |
Blotting, Northern | 12 | 0.0 |
Epitopes/immunology | 2 | 0.0 |
Fetus | 4 | 0.0 |
Infant, Newborn | 18 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Senile Plaques/metabolism/pathology | 7 | 46.0 |
Apolipoprotein A-I/metabolism | 7 | 9.0 |
Apolipoproteins E/*secretion | 5 | 100.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Macrophages/*metabolism | 22 | 9.0 |
Cell Adhesion | 2 | 0.0 |
Chimera | 3 | 1.0 |
Oxidative Stress/genetics | 2 | 8.0 |
Transforming Growth Factor beta/*genetics | 3 | 3.0 |
Apolipoproteins E/*physiology | 27 | 84.0 |
Alzheimer Disease/*drug therapy/*genetics/pathology | 3 | 100.0 |
*Phenotype | 11 | 4.0 |
Bone Marrow Transplantation | 7 | 2.0 |
Cloning, Molecular | 24 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
Apolipoproteins/blood/*genetics | 6 | 37.0 |
Lipoproteins/blood/*genetics | 2 | 28.0 |
Lipoproteins, HDL Cholesterol/blood/genetics | 2 | 15.0 |
Lipoproteins, LDL Cholesterol/blood/genetics | 2 | 28.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Cholesterol/blood/*metabolism | 6 | 27.0 |
Lipoproteins, HDL Cholesterol | 2 | 4.0 |
Transferrin/*genetics | 2 | 4.0 |
African Americans | 4 | 3.0 |
*European Continental Ancestry Group | 2 | 2.0 |
Random Allocation | 7 | 1.0 |
Diabetes Mellitus, Type 2/*blood/genetics | 2 | 33.0 |
Alzheimer Disease/*enzymology | 2 | 4.0 |
*Microsatellite Repeats | 2 | 0.0 |
Cholesterol Esters/blood | 10 | 8.0 |
Coronary Disease/genetics | 7 | 20.0 |
Esterification | 3 | 3.0 |
Fasting | 8 | 2.0 |
Gestational Age | 4 | 0.0 |
Hypertriglyceridemia/*genetics | 5 | 41.0 |
Lipoprotein Lipase/*genetics/metabolism | 4 | 12.0 |
Aging | 14 | 4.0 |
Apolipoproteins C/genetics | 13 | 37.0 |
Smoking | 8 | 2.0 |
Aging/*genetics | 8 | 14.0 |
Cognition | 7 | 13.0 |
Memory Disorders/*genetics | 2 | 50.0 |
3T3 Cells | 5 | 0.0 |
Apolipoproteins/*metabolism | 7 | 17.0 |
COS Cells | 4 | 0.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
DNA/metabolism | 3 | 0.0 |
Fibroblasts/metabolism | 22 | 2.0 |
Genes, Reporter | 6 | 0.0 |
Introns | 12 | 0.0 |
RNA, Messenger/*metabolism | 5 | 0.0 |
Up-Regulation | 8 | 0.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
Lipoprotein Lipase/genetics | 5 | 16.0 |
alpha 1-Antichymotrypsin/genetics | 4 | 66.0 |
Databases, Factual | 2 | 0.0 |
Blood Glucose/metabolism | 6 | 0.0 |
Least-Squares Analysis | 2 | 5.0 |
Alzheimer Disease/genetics/pathology | 5 | 62.0 |
Formaldehyde | 2 | 2.0 |
Prions/*genetics | 3 | 5.0 |
Senile Plaques/pathology | 19 | 54.0 |
Alzheimer Disease/etiology/genetics | 2 | 66.0 |
Cerebral Amyloid Angiopathy/*etiology/*genetics | 2 | 100.0 |
Cerebral Hemorrhage/*etiology/*genetics | 2 | 100.0 |
Alzheimer Disease/etiology/genetics/metabolism | 2 | 100.0 |
Genes, Dominant | 3 | 0.0 |
Mutation, Missense | 6 | 0.0 |
Alzheimer Disease/*genetics/*pathology | 19 | 79.0 |
Atrophy | 12 | 8.0 |
Gene Dosage | 12 | 3.0 |
Hippocampus/*pathology | 8 | 15.0 |
Brain/pathology | 35 | 10.0 |
Cephalometry | 3 | 11.0 |
*Genetic Screening | 6 | 3.0 |
Informed Consent | 2 | 22.0 |
*Pedigree | 2 | 6.0 |
*Truth Disclosure | 2 | 20.0 |
Alzheimer Disease/genetics/physiopathology | 3 | 42.0 |
Brain/physiopathology | 3 | 5.0 |
Enhancer Elements (Genetics) | 3 | 0.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Hypoglycemic Agents/pharmacology | 2 | 6.0 |
Insulin/metabolism | 2 | 1.0 |
Macrophages/cytology/drug effects/metabolism | 2 | 11.0 |
Promoter Regions (Genetics) | 21 | 0.0 |
Apolipoproteins E/*deficiency | 7 | 70.0 |
Blood Pressure/drug effects | 3 | 0.0 |
Cholesterol, Dietary | 3 | 21.0 |
Lipoproteins, VLDL Cholesterol/blood | 8 | 12.0 |
Receptors, Endothelin/*antagonists & inhibitors | 2 | 15.0 |
ATP-Binding Cassette Transporters/metabolism | 2 | 4.0 |
DNA, Complementary | 2 | 0.0 |
Lipoproteins, LDL/pharmacology | 3 | 7.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Cholesterol Esters/*metabolism | 2 | 2.0 |
Receptors, Immunologic/metabolism | 7 | 4.0 |
Alzheimer Disease/*metabolism/pathology | 16 | 17.0 |
Apolipoproteins E/*analysis | 20 | 80.0 |
*Brain Chemistry | 6 | 3.0 |
Neurofibrillary Tangles/*chemistry/pathology | 2 | 100.0 |
Senile Plaques/chemistry/pathology | 2 | 50.0 |
Brain/metabolism/pathology/physiopathology | 3 | 27.0 |
Coronary Disease/blood/*genetics | 3 | 15.0 |
Alkaline Phosphatase/blood | 2 | 1.0 |
Bone Density | 2 | 1.0 |
Bone and Bones/*metabolism | 2 | 2.0 |
Denmark | 6 | 3.0 |
Osteocalcin/blood | 2 | 2.0 |
Coronary Arteriosclerosis/*genetics | 2 | 8.0 |
Heparan Sulfate Proteoglycan/metabolism | 2 | 7.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Platelet-Derived Growth Factor/pharmacology | 3 | 1.0 |
Amyloid beta-Protein/*physiology | 4 | 66.0 |
Lipids/analysis | 2 | 4.0 |
Lipoproteins, HDL/chemistry | 2 | 22.0 |
Phospholipids/analysis | 3 | 8.0 |
Arteriosclerosis/*prevention & control | 2 | 11.0 |
Gene Therapy | 3 | 0.0 |
Injections, Intraventricular | 3 | 2.0 |
Iron/pharmacology | 3 | 16.0 |
Rats, Sprague-Dawley | 21 | 0.0 |
Hispanic Americans/genetics | 5 | 12.0 |
*Mortality | 4 | 16.0 |
Alzheimer Disease/genetics/*metabolism/pathology | 6 | 60.0 |
Brain/*metabolism/pathology | 10 | 12.0 |
Phospholipids/*metabolism | 5 | 4.0 |
Tissue Distribution | 17 | 0.0 |
Italy | 19 | 3.0 |
Ventricular Dysfunction, Left/*genetics | 2 | 100.0 |
Cognition Disorders/epidemiology/*genetics | 2 | 100.0 |
Brain/*metabolism | 24 | 5.0 |
CHO Cells | 9 | 0.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Endocytosis | 6 | 1.0 |
Glycoproteins/metabolism | 4 | 2.0 |
Hamsters | 19 | 0.0 |
LDL-Receptor Related Protein-Associated Protein | 3 | 27.0 |
Lipoproteins, HDL/metabolism | 10 | 9.0 |
Antibodies, Monoclonal/immunology | 5 | 0.0 |
Apolipoproteins B/metabolism | 6 | 6.0 |
Apolipoproteins E/*analysis/genetics/immunology | 2 | 100.0 |
Kinetics | 61 | 0.0 |
Liver/metabolism | 25 | 3.0 |
Models, Biological | 13 | 0.0 |
Aldehydes/*metabolism | 3 | 21.0 |
Neuroglia/metabolism/pathology | 3 | 21.0 |
Alzheimer Disease/*genetics/physiopathology | 8 | 72.0 |
Brain-Derived Neurotrophic Factor/*genetics | 2 | 4.0 |
Polymerase Chain Reaction/methods | 7 | 0.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
Finland/epidemiology | 11 | 9.0 |
Interleukin-6/*genetics | 4 | 5.0 |
Pilot Projects | 7 | 1.0 |
Binding Sites | 25 | 0.0 |
Cell Line, Tumor | 10 | 0.0 |
Protein Isoforms/chemistry/genetics/metabolism | 2 | 4.0 |
Sequence Alignment | 6 | 0.0 |
Signal Transduction | 7 | 0.0 |
Astrocytes/metabolism/pathology | 2 | 7.0 |
Brain/metabolism/pathology | 15 | 14.0 |
Half-Life | 4 | 0.0 |
Peptide Fragments/*pharmacology | 3 | 1.0 |
Protein Binding/drug effects | 2 | 0.0 |
Fluorescent Dyes | 5 | 1.0 |
Neuroglia/physiology | 2 | 13.0 |
Thiazoles | 4 | 7.0 |
Apolipoproteins E/genetics/*metabolism/pharmacology | 3 | 100.0 |
Astrocytes/*metabolism/secretion | 2 | 100.0 |
Coculture Techniques | 2 | 0.0 |
Culture Media, Conditioned/pharmacology | 4 | 2.0 |
Transfection/methods | 2 | 1.0 |
Body Constitution | 2 | 1.0 |
Body Mass Index | 27 | 2.0 |
Genetic Markers/genetics | 7 | 1.0 |
Netherlands/epidemiology | 4 | 3.0 |
Tunica Intima/ultrasonography | 2 | 10.0 |
Tunica Media/ultrasonography | 2 | 11.0 |
Alzheimer Disease/epidemiology/genetics | 4 | 80.0 |
Memory | 3 | 15.0 |
Membrane Proteins/genetics | 18 | 4.0 |
Tomography, X-Ray Computed | 5 | 0.0 |
Treatment Outcome | 17 | 0.0 |
Calorimetry | 2 | 3.0 |
Thermodynamics | 4 | 1.0 |
Apolipoprotein A-I/*genetics/metabolism | 4 | 40.0 |
Immunoenzyme Techniques | 11 | 0.0 |
Dementia, Vascular/epidemiology/*genetics | 2 | 66.0 |
Apolipoproteins/metabolism | 6 | 15.0 |
Apolipoproteins B/*metabolism | 3 | 3.0 |
Dose-Response Relationship, Drug | 28 | 0.0 |
Lipoproteins, LDL/pharmacokinetics | 2 | 40.0 |
Gene Frequency/genetics | 26 | 5.0 |
Japan | 27 | 1.0 |
Statistics, Nonparametric | 10 | 0.0 |
Arteriosclerosis/*ethnology/*genetics | 2 | 100.0 |
Fetal Blood | 2 | 1.0 |
Biotinylation | 3 | 2.0 |
Cattle | 15 | 0.0 |
Chromatography, Affinity | 15 | 1.0 |
Heparan Sulfate Proteoglycan/chemistry/*metabolism | 2 | 66.0 |
Hydrogen-Ion Concentration | 14 | 1.0 |
Lysine/chemistry | 3 | 3.0 |
Surface Plasmon Resonance | 6 | 3.0 |
RNA, Messenger/analysis | 15 | 0.0 |
LDL-Receptor Related Protein 1 | 34 | 30.0 |
Microsatellite Repeats/genetics | 3 | 0.0 |
Northern Ireland | 2 | 9.0 |
Aging/*metabolism | 8 | 3.0 |
Nerve Degeneration/pathology | 2 | 13.0 |
Neurofibrillary Tangles/pathology | 30 | 58.0 |
Neuropil/pathology | 2 | 40.0 |
tau Proteins/*metabolism | 7 | 15.0 |
Amyloid beta-Protein/metabolism | 16 | 30.0 |
Neurons/metabolism/pathology | 3 | 4.0 |
Apolipoproteins E/chemistry/genetics/*metabolism | 6 | 100.0 |
Hydrolysis | 9 | 1.0 |
Spectrometry, Fluorescence | 15 | 3.0 |
Apolipoproteins/*genetics | 20 | 29.0 |
Bone Marrow Cells/metabolism | 2 | 2.0 |
Immunoblotting | 34 | 1.0 |
Macrophages, Peritoneal/metabolism | 2 | 8.0 |
Retroviridae/*genetics/metabolism | 2 | 22.0 |
Cues | 2 | 10.0 |
Learning/physiology | 2 | 13.0 |
Motor Activity/physiology | 2 | 2.0 |
Weight Loss | 2 | 1.0 |
Aging/genetics | 5 | 13.0 |
Longevity/*genetics | 8 | 22.0 |
Exercise | 3 | 2.0 |
Apolipoproteins E/*deficiency/genetics | 21 | 91.0 |
Diet, Atherogenic | 6 | 18.0 |
*Gene Expression | 7 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Amyloid/metabolism | 9 | 20.0 |
Apolipoproteins E/physiology | 2 | 40.0 |
Neurons/metabolism | 14 | 4.0 |
Coronary Disease/epidemiology/*etiology/*genetics | 2 | 100.0 |
Great Britain/epidemiology | 5 | 4.0 |
Brain/metabolism/*pathology | 4 | 12.0 |
Cell Survival | 2 | 0.0 |
DNA/blood | 4 | 2.0 |
*Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Circular Dichroism | 12 | 2.0 |
Polymers/metabolism | 2 | 4.0 |
Area Under Curve | 4 | 0.0 |
Calcium Signaling | 2 | 2.0 |
Alzheimer Disease/genetics/*physiopathology | 5 | 71.0 |
tau Proteins/metabolism | 18 | 26.0 |
Alzheimer Disease | 5 | 33.0 |
Acyltransferases/*genetics | 3 | 6.0 |
Cognition Disorders/genetics | 2 | 22.0 |
Frontal Lobe/*metabolism/pathology | 3 | 50.0 |
Neurofibrillary Tangles/*pathology | 7 | 31.0 |
Peptide Fragments/metabolism | 15 | 4.0 |
Microscopy, Electron | 21 | 1.0 |
Phospholipids/*cerebrospinal fluid | 2 | 100.0 |
Apolipoproteins E/*blood | 36 | 65.0 |
Chromatography, High Pressure Liquid | 14 | 0.0 |
Chylomicrons/blood | 2 | 5.0 |
Heparin | 3 | 4.0 |
Indicators and Reagents | 3 | 1.0 |
Lipoproteins, VLDL/blood | 27 | 12.0 |
Precipitation | 4 | 2.0 |
Sensitivity and Specificity | 22 | 0.0 |
Cerebrovascular Accident/epidemiology/*genetics | 2 | 25.0 |
Alzheimer Disease/genetics | 19 | 44.0 |
DNA/analysis | 25 | 2.0 |
Arteriosclerosis/etiology/*genetics | 2 | 50.0 |
Postprandial Period | 5 | 5.0 |
Apolipoproteins E/*chemistry/genetics/*metabolism | 2 | 100.0 |
Escherichia coli | 3 | 0.0 |
Peptide Fragments/chemistry/metabolism | 4 | 3.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
Biological Transport | 13 | 0.0 |
*Sex Factors | 2 | 14.0 |
Apolipoproteins E/*cerebrospinal fluid | 12 | 100.0 |
Electrophoresis, Gel, Two-Dimensional/methods | 2 | 9.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods | 2 | 10.0 |
*Ethnic Groups | 3 | 2.0 |
Anticholesteremic Agents/therapeutic use | 3 | 9.0 |
Apolipoproteins E | 23 | 76.0 |
Biological Markers | 13 | 0.0 |
Cross-Over Studies | 7 | 1.0 |
Hypoglycemic Agents/therapeutic use | 2 | 4.0 |
Arteriosclerosis/etiology/metabolism | 2 | 33.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Arteriosclerosis/metabolism/*physiopathology | 2 | 100.0 |
Calcium/metabolism | 3 | 0.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
Superoxides/metabolism | 2 | 0.0 |
Vasodilation | 2 | 5.0 |
Alzheimer Disease/genetics/metabolism/*physiopathology | 3 | 75.0 |
Hippocampus/metabolism/pathology/physiopathology | 3 | 37.0 |
Lipoproteins, LDL Cholesterol/*blood | 8 | 9.0 |
Receptors, Dopamine D2/*genetics | 2 | 0.0 |
Amyloid beta-Protein Precursor/*metabolism | 8 | 11.0 |
Chromatography, High Pressure Liquid/methods | 3 | 2.0 |
Cricetulus | 2 | 0.0 |
Drug Interactions | 2 | 0.0 |
Embryo | 2 | 0.0 |
Endopeptidases/*metabolism | 2 | 1.0 |
Kidney | 2 | 0.0 |
Neuroblastoma | 3 | 1.0 |
Triglycerides/pharmacology | 2 | 22.0 |
Cerebrovascular Accident/genetics | 2 | 33.0 |
Cerebrovascular Disorders/*genetics | 4 | 44.0 |
Apolipoprotein A-I/*blood | 4 | 12.0 |
Apolipoproteins C/blood | 9 | 31.0 |
Aorta/cytology | 2 | 2.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Cholesterol Esters/metabolism | 12 | 11.0 |
Glucose/metabolism | 3 | 1.0 |
Macrophages/*physiology | 2 | 2.0 |
*Neoplasm Proteins | 7 | 0.0 |
*Nerve Tissue Proteins | 4 | 0.0 |
*Tumor Suppressor Proteins | 7 | 0.0 |
Brain/cytology/drug effects/*metabolism | 2 | 33.0 |
Heymann Nephritis Antigenic Complex | 5 | 22.0 |
Neurons/drug effects/metabolism | 2 | 4.0 |
Genes, Structural/*genetics | 2 | 0.0 |
Receptors, Immunologic/genetics | 3 | 7.0 |
Tumor Necrosis Factor-alpha/genetics | 2 | 0.0 |
alpha-Macroglobulins/genetics | 5 | 38.0 |
Hippocampus/pathology/physiopathology | 2 | 50.0 |
Hypertension/complications | 4 | 6.0 |
*Magnetic Resonance Imaging | 6 | 3.0 |
Memory/physiology | 3 | 9.0 |
Lac Operon | 2 | 1.0 |
Lipoproteins/metabolism | 11 | 10.0 |
Myocardium/metabolism | 2 | 0.0 |
Cysteamine/chemistry | 2 | 100.0 |
Dimyristoylphosphatidylcholine/chemistry | 3 | 75.0 |
*Biosensing Techniques | 3 | 11.0 |
DNA Probes | 2 | 0.0 |
Electrochemistry | 2 | 2.0 |
Coronary Disease/etiology | 3 | 8.0 |
*Heterozygote | 10 | 3.0 |
*Developing Countries | 2 | 6.0 |
*Genetics, Population | 4 | 1.0 |
India | 5 | 1.0 |
Apolipoproteins B/*genetics | 10 | 5.0 |
Colombia | 2 | 4.0 |
Ethnic Groups/genetics | 3 | 1.0 |
Genetic Heterogeneity | 3 | 1.0 |
Myocardial Infarction/genetics | 5 | 20.0 |
Peptidyl-Dipeptidase A/*genetics | 25 | 7.0 |
Carotid Arteries/*pathology/ultrasonography | 5 | 35.0 |
Japan/epidemiology | 13 | 3.0 |
Renin-Angiotensin System/genetics | 2 | 8.0 |
Biological Transport, Active/genetics | 2 | 33.0 |
Lipoproteins/blood/*metabolism | 5 | 16.0 |
Lipoproteins, VLDL/secretion | 2 | 33.0 |
Liver/secretion | 2 | 50.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Sampling Studies | 6 | 3.0 |
Polymorphism, Genetic/*physiology | 5 | 7.0 |
Cognition Disorders/*genetics/psychology | 4 | 100.0 |
Psychiatric Status Rating Scales | 23 | 11.0 |
Apolipoproteins E/blood/chemistry/*genetics | 3 | 100.0 |
Electrophoresis, Gel, Two-Dimensional | 10 | 3.0 |
Isoelectric Point | 4 | 3.0 |
DNA/chemistry | 3 | 1.0 |
Glasgow Coma Scale | 5 | 18.0 |
Rural Population | 6 | 6.0 |
Apolipoproteins/*blood | 28 | 17.0 |
Astrocytes/pathology | 4 | 11.0 |
Cerebral Cortex/*metabolism/pathology | 3 | 23.0 |
Senile Plaques/*metabolism | 3 | 37.0 |
Gene Expression Regulation | 17 | 0.0 |
Mitosis | 2 | 0.0 |
Population Surveillance | 6 | 3.0 |
*Gene Therapy | 7 | 1.0 |
Hippocampus/metabolism | 5 | 5.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Lipids/chemistry/metabolism | 2 | 14.0 |
Lipoproteins, HDL Cholesterol/metabolism | 4 | 8.0 |
Monocytes/metabolism | 6 | 1.0 |
Chromosomes, Human/genetics | 2 | 4.0 |
Alzheimer Disease/*cerebrospinal fluid/genetics | 2 | 66.0 |
Estrogen Replacement Therapy | 2 | 4.0 |
Hyperlipidemia/complications | 3 | 21.0 |
Alzheimer Disease/*genetics/*metabolism | 9 | 56.0 |
Drug Delivery Systems/*methods | 2 | 5.0 |
Tumor Cells, Cultured/metabolism | 3 | 1.0 |
Apolipoproteins B/genetics | 6 | 16.0 |
Czech Republic | 3 | 6.0 |
Insulin/*blood | 3 | 1.0 |
Cerebral Amyloid Angiopathy/*metabolism/pathology | 2 | 100.0 |
Health Status | 3 | 3.0 |
Lipoprotein(a)/*blood | 5 | 5.0 |
Tunica Intima/*pathology | 3 | 15.0 |
Down Syndrome/genetics | 2 | 7.0 |
Cathepsin D/*genetics | 4 | 25.0 |
*Genotype | 23 | 10.0 |
Germany | 2 | 0.0 |
*Frontal Lobe | 2 | 33.0 |
Linkage (Genetics)/genetics | 5 | 1.0 |
Microsatellite Repeats | 6 | 0.0 |
Lipoproteins, HDL/*metabolism | 7 | 5.0 |
Lipoproteins, LDL/*metabolism | 14 | 7.0 |
alpha 1-Antichymotrypsin/*genetics/metabolism | 2 | 66.0 |
Fibroblasts/enzymology/metabolism | 2 | 11.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Protein Processing, Post-Translational | 4 | 0.0 |
Dietary Fats/metabolism | 4 | 12.0 |
Mutation/genetics | 3 | 0.0 |
*Alzheimer Disease/epidemiology/genetics/metabolism | 2 | 100.0 |
Korea/epidemiology | 3 | 5.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Transcription Factors/*genetics | 4 | 0.0 |
Cerebrovascular Circulation/*genetics | 2 | 100.0 |
*Tomography, Emission-Computed, Single-Photon | 3 | 10.0 |
Geography | 4 | 6.0 |
Apolipoproteins E/analysis/*genetics | 12 | 80.0 |
*Herpesvirus 1, Human | 2 | 20.0 |
*Coronary Artery Bypass | 2 | 2.0 |
Coronary Disease/etiology/genetics | 2 | 40.0 |
Dietary Fats/*pharmacology | 8 | 12.0 |
Lipoproteins, LDL Cholesterol/*blood/genetics | 3 | 50.0 |
Cognition/*drug effects | 4 | 22.0 |
Membrane Proteins/*genetics/metabolism | 2 | 1.0 |
tau Proteins/*cerebrospinal fluid | 7 | 70.0 |
Heparin/chemistry/*metabolism | 3 | 21.0 |
Oligosaccharides/chemistry/metabolism | 2 | 13.0 |
Peptide Fragments/chemistry/*metabolism | 2 | 10.0 |
Swine | 5 | 0.0 |
Cholesterol, Dietary/*pharmacology | 6 | 42.0 |
Coronary Disease/epidemiology/genetics | 2 | 28.0 |
Massachusetts | 2 | 11.0 |
Myocardial Infarction/blood/genetics | 2 | 33.0 |
Brain/metabolism/*physiopathology | 2 | 25.0 |
Neoplasm Staging | 3 | 0.0 |
Randomized Controlled Trials | 4 | 0.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Apolipoproteins E/analysis/*genetics/*metabolism | 2 | 100.0 |
Brain/*cytology | 2 | 14.0 |
Gene Expression/physiology | 7 | 2.0 |
Neurons/chemistry/cytology/*metabolism | 3 | 60.0 |
*Linkage (Genetics) | 17 | 1.0 |
Lipopolysaccharides/pharmacology | 4 | 0.0 |
Ethnic Groups/*genetics | 7 | 3.0 |
Mexico | 2 | 2.0 |
Abdomen | 3 | 3.0 |
Cardiovascular Diseases/prevention & control | 2 | 15.0 |
Insulin/blood | 7 | 1.0 |
Insulin Resistance | 4 | 2.0 |
Fasting/blood | 2 | 3.0 |
Hypertriglyceridemia/*blood | 5 | 12.0 |
Lipoprotein(a)/blood | 4 | 6.0 |
Osmolar Concentration | 3 | 0.0 |
Alzheimer Disease/epidemiology/genetics/*metabolism | 3 | 100.0 |
Cerebral Cortex/*metabolism | 2 | 3.0 |
Astrocytes/metabolism | 4 | 5.0 |
Carcinoma, Hepatocellular/*metabolism | 3 | 2.0 |
Forskolin/pharmacology | 2 | 0.0 |
Hydroxycholesterols/metabolism | 3 | 17.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Interleukin-1/pharmacology | 3 | 0.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Liver Neoplasms/*metabolism | 3 | 3.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
Nucleic Acid Hybridization | 14 | 0.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
Introns/genetics | 6 | 0.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Fluorescence Polarization | 6 | 10.0 |
Liver Neoplasms/metabolism | 2 | 2.0 |
Triglycerides/blood/metabolism | 4 | 18.0 |
Triolein | 2 | 33.0 |
Apolipoproteins E/blood/genetics | 6 | 37.0 |
Electrodes | 2 | 4.0 |
Penetrance | 3 | 2.0 |
Heparin/*metabolism | 6 | 7.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Accidental Falls | 2 | 66.0 |
*Algorithms | 2 | 3.0 |
Binding, Competitive | 19 | 1.0 |
Carbon Radioisotopes | 2 | 2.0 |
Cell Division/*drug effects | 2 | 0.0 |
Heparin Lyase/metabolism | 2 | 50.0 |
Iodine Radioisotopes | 7 | 1.0 |
Muscle, Smooth, Vascular/cytology/*drug effects/metabolism | 2 | 11.0 |
Coronary Disease/*etiology/genetics | 2 | 50.0 |
Parkinson Disease/*genetics | 12 | 14.0 |
Central Nervous System/*metabolism | 2 | 5.0 |
Double-Blind Method | 23 | 1.0 |
*Heterozygote Detection | 5 | 4.0 |
Alzheimer Disease/etiology/*metabolism/pathology | 2 | 66.0 |
Oxidative Stress | 4 | 1.0 |
Alzheimer Disease/*blood/epidemiology | 2 | 100.0 |
Nerve Tissue Proteins/*genetics | 4 | 0.0 |
Point Mutation/genetics | 6 | 2.0 |
Gene Expression Regulation/*genetics | 3 | 2.0 |
Receptors, LDL/*genetics/*metabolism | 2 | 40.0 |
RNA, Messenger/*genetics | 4 | 1.0 |
Matched-Pair Analysis | 3 | 3.0 |
Survivors | 3 | 3.0 |
Arginine/*genetics | 2 | 3.0 |
Restriction Mapping | 9 | 0.0 |
Androstadienes/pharmacology | 2 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Neurons/drug effects/*metabolism | 3 | 8.0 |
Brain Ischemia/*genetics | 4 | 28.0 |
Alzheimer Disease/diagnosis/epidemiology/*genetics | 2 | 66.0 |
Sweden/epidemiology | 4 | 3.0 |
Astrocytes/cytology/*metabolism | 3 | 17.0 |
Brain/cytology/*metabolism | 5 | 10.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Organ Specificity | 11 | 0.0 |
Promoter Regions (Genetics)/physiology | 3 | 1.0 |
Transgenes/genetics | 4 | 5.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Retinoid X Receptors | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Extracellular Space/metabolism | 2 | 3.0 |
Muscle, Smooth, Vascular/metabolism | 2 | 3.0 |
Protein Binding/physiology | 7 | 2.0 |
Proteoglycans/*metabolism | 5 | 7.0 |
Macular Degeneration/*genetics | 6 | 12.0 |
*Health Status | 2 | 5.0 |
Apolipoproteins E/analysis/genetics | 2 | 100.0 |
Cholesterol Esters/biosynthesis | 4 | 28.0 |
Macrophages, Peritoneal/*metabolism | 3 | 14.0 |
Mice, Transgenic/genetics | 7 | 12.0 |
Liver/*metabolism | 14 | 3.0 |
Electroencephalography | 3 | 1.0 |
Tomography, Emission-Computed | 4 | 3.0 |
Chromosomes, Human, Pair 10/*genetics | 2 | 1.0 |
Nuclear Family | 7 | 2.0 |
Apolipoproteins E/*metabolism/pharmacology | 4 | 100.0 |
Sodium Dodecyl Sulfate | 2 | 3.0 |
Lipoproteins, LDL/*physiology | 3 | 50.0 |
*Membrane Transport Proteins | 5 | 0.0 |
Protein Biosynthesis | 6 | 0.0 |
Sequence Homology, Amino Acid | 9 | 0.0 |
Triglycerides/metabolism | 6 | 3.0 |
*Blood-Brain Barrier | 2 | 8.0 |
alpha-Macroglobulins/metabolism | 2 | 4.0 |
Antibodies/pharmacology | 2 | 0.0 |
Arteriosclerosis/*etiology | 2 | 5.0 |
Endothelium, Vascular/enzymology | 2 | 4.0 |
Necrosis | 3 | 0.0 |
Dementia/*genetics/*pathology | 4 | 80.0 |
Carrier Proteins/blood | 3 | 2.0 |
Mice, Inbred Strains | 9 | 1.0 |
Mice, Knockout/genetics | 4 | 10.0 |
Receptor, Angiotensin, Type 1 | 2 | 1.0 |
Receptor, Angiotensin, Type 2 | 2 | 2.0 |
Electrophoresis, Polyacrylamide Gel/methods | 6 | 5.0 |
Gene Library | 3 | 0.0 |
Stochastic Processes | 2 | 5.0 |
DNA/analysis/genetics | 6 | 4.0 |
Rabbits | 26 | 0.0 |
Receptors, Lipoprotein/metabolism | 4 | 40.0 |
*Sequence Deletion | 2 | 0.0 |
Apolipoproteins E/genetics/*pharmacology | 5 | 83.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Gene Expression/drug effects/physiology | 2 | 4.0 |
Tretinoin/pharmacology | 2 | 0.0 |
China/ethnology | 5 | 2.0 |
Dementia/metabolism | 2 | 66.0 |
Parkinson Disease/metabolism | 2 | 11.0 |
Research Design | 5 | 5.0 |
Behavior, Animal | 2 | 2.0 |
Bone Density/*genetics | 2 | 1.0 |
Apolipoproteins E/*drug effects/metabolism | 2 | 66.0 |
Aging/*psychology | 3 | 50.0 |
Netherlands | 7 | 4.0 |
Verbal Learning | 2 | 40.0 |
Amyloid beta-Protein Precursor/metabolism | 5 | 14.0 |
Alzheimer Disease/*diagnosis/epidemiology/*genetics | 3 | 100.0 |
Genetic Screening/methods | 3 | 2.0 |
Arteriosclerosis/genetics/*metabolism/pathology | 2 | 40.0 |
Cholesterol, Dietary/administration & dosage | 2 | 7.0 |
RNA/analysis | 3 | 1.0 |
France/epidemiology | 3 | 2.0 |
Apolipoproteins E/*deficiency/*genetics | 2 | 66.0 |
Cholesterol/blood/metabolism | 4 | 21.0 |
Apolipoproteins C/*blood | 5 | 16.0 |
Hyperlipidemia/blood | 2 | 5.0 |
Lipoproteins, VLDL/*blood | 9 | 12.0 |
Chromatography, Gel | 19 | 2.0 |
Micelles | 2 | 4.0 |
Nerve Tissue Proteins/*metabolism | 4 | 1.0 |
Amino Acid Sequence/genetics | 2 | 0.0 |
Disability Evaluation | 6 | 16.0 |
Multiple Sclerosis/*genetics/*physiopathology | 2 | 66.0 |
Intracellular Membranes/metabolism | 2 | 1.0 |
Protein Isoforms/metabolism | 5 | 2.0 |
Models, Neurological | 3 | 2.0 |
Mutation/physiology | 2 | 1.0 |
Carrier Proteins/genetics | 10 | 2.0 |
Isoenzymes/genetics | 2 | 0.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Receptors, Dopamine D2/genetics | 3 | 6.0 |
Lipids/genetics/*metabolism | 2 | 50.0 |
Lipoproteins, VLDL/genetics/*metabolism | 3 | 100.0 |
*Kidney Transplantation | 2 | 0.0 |
*Renal Dialysis | 5 | 1.0 |
*Aging | 5 | 3.0 |
Brain/growth & development/*metabolism/pathology | 2 | 66.0 |
Down Syndrome/*genetics | 8 | 11.0 |
Meiosis/*genetics | 2 | 5.0 |
Apolipoproteins E/deficiency/genetics/*physiology | 4 | 100.0 |
Disease Susceptibility | 14 | 1.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Acute Disease | 3 | 0.0 |
Antibodies | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Neurotoxins/pharmacology | 3 | 14.0 |
Circadian Rhythm/physiology | 2 | 3.0 |
Cognition Disorders/diagnosis | 4 | 30.0 |
Tomography, Emission-Computed, Single-Photon | 2 | 3.0 |
Neuroprotective Agents/metabolism/pharmacology | 2 | 66.0 |
Blood Glucose/analysis | 3 | 0.0 |
Bayes Theorem | 3 | 5.0 |
Canada | 6 | 4.0 |
India/ethnology | 5 | 7.0 |
Brain/*physiology | 3 | 2.0 |
Image Processing, Computer-Assisted | 9 | 2.0 |
Placebos | 5 | 2.0 |
*Gene Expression Regulation | 14 | 0.0 |
Dementia, Vascular/*genetics | 10 | 83.0 |
alpha 1-Antitrypsin/*genetics | 3 | 11.0 |
Cholesterol, Dietary/metabolism | 3 | 37.0 |
Arteriosclerosis/*blood | 3 | 14.0 |
Fatty Acids, Nonesterified/blood | 2 | 1.0 |
Food | 2 | 1.0 |
Lipolysis | 8 | 9.0 |
*Endocytosis | 2 | 1.0 |
*Molecular Chaperones | 7 | 4.0 |
Receptors, Lipoprotein/*metabolism | 2 | 12.0 |
Alzheimer Disease/*genetics/metabolism/pathology | 6 | 50.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Apolipoproteins E/cerebrospinal fluid/metabolism | 2 | 100.0 |
Oxidation-Reduction | 9 | 0.0 |
Amyloid beta-Protein Precursor/genetics/metabolism | 2 | 14.0 |
Chromosomes, Human, Pair 19 | 12 | 6.0 |
Genes, Regulator | 2 | 1.0 |
*Genetic Heterogeneity | 4 | 2.0 |
Nerve Degeneration/genetics/pathology | 2 | 50.0 |
Alzheimer Disease/epidemiology/*genetics/pathology | 2 | 100.0 |
Hypercholesterolemia, Familial/genetics | 3 | 27.0 |
Neurons/chemistry/pathology | 2 | 66.0 |
tau Proteins/analysis | 2 | 14.0 |
Alzheimer Disease/genetics/*metabolism/*pathology | 4 | 66.0 |
Point Mutation/*genetics | 4 | 1.0 |
Gemfibrozil/pharmacology | 3 | 75.0 |
Hyperlipoproteinemia Type IV/*blood | 3 | 25.0 |
Cognition/drug effects | 4 | 26.0 |
Alzheimer Disease/*drug therapy/genetics | 3 | 100.0 |
Gene Targeting | 4 | 1.0 |
Genetic Techniques | 3 | 3.0 |
Cats | 2 | 0.0 |
Hyperlipoproteinemia Type III/genetics/metabolism | 2 | 100.0 |
Apolipoproteins E/*genetics/*physiology | 3 | 75.0 |
Neurons/*physiology | 3 | 2.0 |
Diabetes Complications | 4 | 2.0 |
Smoking/adverse effects | 4 | 1.0 |
Arteriosclerosis/etiology | 6 | 8.0 |
Chylomicrons/*blood | 3 | 10.0 |
Insulin/*pharmacology | 2 | 0.0 |
Lipase/genetics | 2 | 40.0 |
Hydroxycholesterols/*blood | 2 | 66.0 |
Chromosomes, Human, Pair 19/*ultrastructure | 2 | 25.0 |
Monte Carlo Method | 2 | 2.0 |
Quantitative Trait Loci | 2 | 11.0 |
Brain/*pathology | 23 | 15.0 |
Senile Plaques/*pathology | 4 | 66.0 |
Confounding Factors (Epidemiology) | 3 | 4.0 |
Hemochromatosis/*genetics | 2 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 2 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Amyloid beta-Protein/*chemistry | 3 | 42.0 |
Apolipoproteins E/*chemistry | 8 | 100.0 |
Peptides/*metabolism | 2 | 1.0 |
Hong Kong/epidemiology | 2 | 7.0 |
Kainic Acid/pharmacology | 2 | 14.0 |
Blood Vessels/pathology | 2 | 5.0 |
Cerebral Cortex/blood supply/pathology | 2 | 100.0 |
*Cerebrovascular Circulation | 2 | 5.0 |
Neurites/pathology | 6 | 60.0 |
Silver Staining | 2 | 2.0 |
Nitric-Oxide Synthase/*genetics | 3 | 3.0 |
Diabetic Nephropathies/genetics | 2 | 28.0 |
Cell Survival/drug effects | 3 | 0.0 |
Apolipoproteins E/*chemistry/genetics | 2 | 66.0 |
Cysteine/genetics | 5 | 4.0 |
Fluoresceins | 2 | 3.0 |
Nephelometry and Turbidimetry | 3 | 4.0 |
*Protein Conformation | 2 | 0.0 |
Microtubule-Associated Proteins/analysis | 2 | 5.0 |
Chromosomes, Human, Pair 19/genetics | 5 | 4.0 |
Cerebral Cortex/pathology | 5 | 10.0 |
Seroepidemiologic Studies | 2 | 1.0 |
*Introns | 2 | 0.0 |
Apolipoproteins E/genetics/*metabolism/*pharmacology | 2 | 100.0 |
Biological Transport/drug effects | 3 | 1.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Alzheimer Disease/ethnology/*genetics | 4 | 66.0 |
Longevity | 4 | 20.0 |
Alzheimer Disease/cerebrospinal fluid/*diagnosis/genetics | 2 | 100.0 |
Denmark/epidemiology | 3 | 5.0 |
*Sex Characteristics | 9 | 6.0 |
Parkinson Disease/complications/*genetics | 2 | 40.0 |
Apolipoproteins E/*deficiency/pharmacology | 2 | 100.0 |
Diabetes Mellitus, Type 2/*blood/*genetics | 2 | 28.0 |
Parents | 2 | 2.0 |
Asia/epidemiology | 2 | 12.0 |
Europe/epidemiology | 5 | 5.0 |
Cysteine Proteinase Inhibitors/*metabolism | 2 | 18.0 |
Hippocampus/cytology | 6 | 15.0 |
Isomerism | 10 | 4.0 |
Lipid Peroxidation/*drug effects | 4 | 12.0 |
Hypercholesterolemia, Familial/*genetics | 6 | 13.0 |
*Models, Genetic | 3 | 2.0 |
Alzheimer Disease/etiology | 4 | 28.0 |
Peptide Fragments/*metabolism | 5 | 3.0 |
Senile Plaques | 2 | 50.0 |
Brain Ischemia/metabolism/*pathology | 2 | 33.0 |
Hippocampus/drug effects/pathology | 2 | 28.0 |
Genetic Predisposition to Disease/epidemiology | 9 | 10.0 |
Mitochondria/*genetics | 2 | 10.0 |
Alzheimer Disease/*etiology/*genetics | 2 | 100.0 |
Chromosomes, Human, Pair 12/*genetics | 3 | 2.0 |
Computer Simulation | 3 | 0.0 |
Software | 4 | 1.0 |
Lipoproteins, VLDL/blood/*secretion | 2 | 100.0 |
Apolipoproteins E/*analysis/genetics | 3 | 100.0 |
False Positive Reactions | 2 | 0.0 |
Senile Plaques/*metabolism/pathology | 2 | 20.0 |
Anticholesteremic Agents/*therapeutic use | 3 | 5.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use | 2 | 4.0 |
Astrocytoma | 2 | 5.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Binding, Competitive/drug effects | 2 | 3.0 |
Heparin/*pharmacology | 2 | 1.0 |
Apolipoproteins E/blood/*metabolism | 4 | 66.0 |
Lipoproteins, HDL/chemistry/metabolism | 2 | 33.0 |
Lipoproteins, LDL/chemistry/*metabolism | 2 | 15.0 |
Temperature | 8 | 0.0 |
Protein Folding | 2 | 0.0 |
Solutions | 2 | 1.0 |
Triglycerides/analysis | 2 | 6.0 |
Amyloid beta-Protein/genetics | 6 | 60.0 |
Chromosome Aberrations/genetics | 3 | 2.0 |
Chromosome Disorders | 4 | 1.0 |
Chromosomes, Human, Pair 1 | 3 | 1.0 |
Chromosomes, Human, Pair 14 | 7 | 4.0 |
Chromosomes, Human, Pair 21 | 5 | 4.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Peptide Fragments/genetics | 2 | 2.0 |
Apolipoproteins E/blood/*deficiency/*genetics | 2 | 100.0 |
*Gene Transfer Techniques | 6 | 1.0 |
Protein Isoforms/genetics | 5 | 1.0 |
Alzheimer Disease/*blood/diagnosis/genetics | 2 | 100.0 |
Dementia, Vascular/*blood/diagnosis/genetics | 2 | 100.0 |
Homeostasis | 6 | 1.0 |
Ontario/epidemiology | 2 | 8.0 |
*Diseases in Twins | 3 | 10.0 |
Mice, Nude | 3 | 0.0 |
Oxidative Stress/*physiology | 2 | 2.0 |
Lipid Peroxidation | 4 | 3.0 |
Thiobarbituric Acid Reactive Substances/analysis | 3 | 14.0 |
Regional Blood Flow/drug effects | 2 | 1.0 |
Hippocampus/pathology | 9 | 25.0 |
Temporal Lobe/pathology | 5 | 26.0 |
*Chromosomes, Human, Pair 12 | 2 | 0.0 |
Alzheimer Disease/*epidemiology/genetics | 4 | 100.0 |
Maternal Age | 2 | 2.0 |
Urban Population | 2 | 1.0 |
Choline O-Acetyltransferase/analysis | 2 | 4.0 |
Frontal Lobe/pathology | 5 | 50.0 |
Dementia, Vascular/epidemiology/genetics | 2 | 100.0 |
African Continental Ancestry Group | 2 | 0.0 |
Myelin P2 Protein/genetics | 2 | 50.0 |
Receptors, Adrenergic, beta/genetics | 2 | 50.0 |
Sequence Analysis, DNA | 11 | 0.0 |
Lipoproteins, VLDL/blood/metabolism | 3 | 33.0 |
Arginine/*metabolism | 3 | 6.0 |
Fertilization in Vitro | 2 | 1.0 |
Molecular Biology | 3 | 1.0 |
Multiple Sclerosis/*genetics/*pathology | 4 | 100.0 |
Peroxidase/*genetics | 3 | 5.0 |
*Aged, 80 and over | 4 | 66.0 |
Europe | 6 | 2.0 |
*Environment | 4 | 8.0 |
Arteriosclerosis/etiology/genetics/metabolism | 2 | 40.0 |
Conserved Sequence | 2 | 0.0 |
Cerebral Cortex/physiopathology | 2 | 8.0 |
*Electroencephalography | 2 | 1.0 |
alpha 1-Antichymotrypsin/*blood | 2 | 22.0 |
Epidemiologic Studies | 2 | 4.0 |
Mexico/ethnology | 2 | 7.0 |
Korea/ethnology | 2 | 11.0 |
Amyloid beta-Protein Precursor/*genetics/metabolism | 2 | 40.0 |
Apolipoproteins E/*genetics/isolation & purification/metabolism | 3 | 75.0 |
Neuroglia/metabolism | 6 | 8.0 |
Evolution, Molecular | 4 | 0.0 |
Primates | 2 | 2.0 |
Hippocampus/*metabolism | 6 | 8.0 |
Neurofibrillary Tangles/metabolism | 5 | 35.0 |
Senile Plaques/metabolism | 2 | 66.0 |
Drug Administration Schedule | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Rats, Wistar | 8 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*physiology | 2 | 3.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Apolipoproteins E/metabolism/*pharmacology | 2 | 100.0 |
HLA-A2 Antigen/*genetics | 2 | 11.0 |
Linkage Disequilibrium/*genetics | 4 | 5.0 |
Coronary Disease/epidemiology/*genetics | 2 | 15.0 |
Apolipoproteins E/chemistry/*genetics | 6 | 85.0 |
Tritium | 4 | 1.0 |
Culture Media, Conditioned | 5 | 1.0 |
Hippocampus/cytology/*metabolism | 2 | 10.0 |
*Nerve Degeneration | 2 | 8.0 |
Lipoproteins, VLDL Cholesterol/drug effects/metabolism | 2 | 100.0 |
RNA, Messenger/*drug effects/metabolism | 2 | 15.0 |
Insulin Resistance/physiology | 3 | 6.0 |
Lipoproteins, LDL/*chemistry | 3 | 14.0 |
Mexican Americans | 2 | 20.0 |
Syndrome | 2 | 0.0 |
Schizophrenia/genetics/*metabolism | 3 | 37.0 |
Alzheimer Disease/*diagnosis/*genetics | 6 | 100.0 |
Frontal Lobe/*pathology | 2 | 22.0 |
Temporal Lobe/*pathology | 3 | 37.0 |
Densitometry | 3 | 2.0 |
*Chromosomes, Human, Pair 19 | 9 | 2.0 |
Cognition Disorders/*etiology/genetics | 3 | 100.0 |
Anticholesteremic Agents/pharmacology | 3 | 6.0 |
Monocytes/*metabolism | 4 | 1.0 |
Forecasting | 4 | 1.0 |
Smell/*physiology | 3 | 30.0 |
Alzheimer Disease/*genetics/metabolism/*pathology | 3 | 100.0 |
Cysteine Endopeptidases/*genetics | 2 | 6.0 |
Apolipoproteins E/deficiency/genetics | 2 | 18.0 |
Alzheimer Disease/*genetics/*metabolism/pathology | 7 | 100.0 |
Hippocampus/*metabolism/pathology | 4 | 11.0 |
Heparin/metabolism | 3 | 2.0 |
Heparitin Sulfate/metabolism | 3 | 7.0 |
Cognition/drug effects/*physiology | 2 | 50.0 |
Apolipoproteins E/*blood/genetics/isolation & purification | 3 | 100.0 |
Heparan Sulfate Proteoglycan/*genetics | 3 | 21.0 |
Synapses/*pathology | 2 | 33.0 |
Apolipoprotein A-II/*metabolism | 2 | 18.0 |
Alzheimer Disease/*blood/*genetics | 2 | 100.0 |
Antioxidants/*pharmacology | 2 | 1.0 |
Free Radical Scavengers/pharmacology | 2 | 3.0 |
Glutathione/metabolism | 2 | 0.0 |
Oxidative Stress/*drug effects | 2 | 5.0 |
Recombinant Proteins/pharmacology | 9 | 0.0 |
Cerebral Cortex/metabolism/pathology | 2 | 11.0 |
*Lipid Peroxidation | 2 | 4.0 |
Multiple Sclerosis, Relapsing-Remitting/*genetics | 2 | 100.0 |
Apolipoprotein A-I/blood/*pharmacology | 2 | 66.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Methionine/metabolism | 5 | 3.0 |
Species Specificity | 14 | 0.0 |
Sulfur Radioisotopes | 2 | 2.0 |
Glycoproteins/genetics | 3 | 3.0 |
Lipoproteins, VLDL/chemistry | 2 | 40.0 |
Arteriosclerosis/genetics | 4 | 13.0 |
Hyperlipidemia/genetics | 3 | 18.0 |
Alzheimer Disease/*diagnosis/genetics | 3 | 100.0 |
Evaluation Studies | 2 | 0.0 |
Genetic Screening/*methods | 2 | 1.0 |
Trinucleotide Repeats | 3 | 2.0 |
Hong Kong | 2 | 4.0 |
Sequence Deletion | 3 | 0.0 |
Glycosylation | 6 | 0.0 |
Peptide Fragments/chemistry | 3 | 1.0 |
Serine Endopeptidases | 2 | 8.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
Arteriosclerosis/*genetics/metabolism | 3 | 50.0 |
*Genes, Structural | 6 | 0.0 |
Atrophy/pathology | 3 | 17.0 |
Neurons/*pathology | 3 | 4.0 |
Cardiovascular Diseases/mortality | 3 | 30.0 |
Obesity/epidemiology | 4 | 16.0 |
Blood Pressure/*genetics | 3 | 5.0 |
Observer Variation | 3 | 2.0 |
Apolipoproteins E/chemistry/*pharmacology | 2 | 100.0 |
Cell Death/drug effects | 2 | 1.0 |
Dizocilpine Maleate/pharmacology | 2 | 11.0 |
Protease Inhibitors/pharmacology | 3 | 1.0 |
Stimulation, Chemical | 2 | 0.0 |
PPAR gamma/genetics | 2 | 66.0 |
Poland | 5 | 3.0 |
Apolipoproteins E/drug effects/*genetics | 2 | 100.0 |
Depression/diagnosis/*epidemiology | 2 | 100.0 |
Gene Expression/*genetics | 2 | 1.0 |
Postmenopause | 3 | 1.0 |
Amyloid beta-Protein/*pharmacology | 2 | 12.0 |
Glial Fibrillary Acidic Protein/metabolism | 3 | 1.0 |
Macaca fascicularis | 2 | 0.0 |
Synaptophysin/metabolism | 4 | 12.0 |
Metabolic Clearance Rate | 4 | 1.0 |
Receptors, LDL | 2 | 20.0 |
Electrophoresis, Polyacrylamide Gel/*methods | 2 | 6.0 |
Mercaptoethanol/chemistry | 2 | 66.0 |
Population | 3 | 10.0 |
Arteriosclerosis/complications | 3 | 30.0 |
Apolipoproteins E/*chemistry/genetics/metabolism | 2 | 100.0 |
Escherichia coli/genetics | 8 | 1.0 |
Cardiovascular Diseases/diagnosis | 2 | 40.0 |
Mental Recall/physiology | 2 | 18.0 |
Wechsler Scales | 3 | 18.0 |
Amyloid beta-Protein/chemistry/*metabolism | 5 | 71.0 |
Arginine/genetics | 2 | 1.0 |
Binding Sites/genetics | 4 | 0.0 |
Carbohydrate Conformation | 3 | 2.0 |
Kidney/cytology | 4 | 2.0 |
Phospholipids/blood | 7 | 5.0 |
Histocytochemistry | 4 | 0.0 |
Alzheimer Disease/metabolism/pathology | 5 | 22.0 |
Laterality | 2 | 3.0 |
Mental Recall | 3 | 23.0 |
Osteoporosis/*genetics | 2 | 8.0 |
Alzheimer Disease/*cerebrospinal fluid | 4 | 22.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Dementia/diagnosis | 3 | 60.0 |
Liver/*enzymology | 4 | 0.0 |
Chromosomes, Human, Pair 12 | 2 | 1.0 |
Apolipoproteins A/blood | 3 | 4.0 |
Indoles/administration & dosage/*therapeutic use | 2 | 33.0 |
Aging/pathology | 4 | 23.0 |
Alzheimer Disease/*pathology | 8 | 15.0 |
Glial Fibrillary Acidic Protein/analysis | 3 | 1.0 |
Thyroid Hormones/blood | 3 | 3.0 |
Thyrotropin/blood | 2 | 0.0 |
Depressive Disorder/*genetics | 3 | 15.0 |
Alzheimer Disease/genetics/psychology | 4 | 100.0 |
Cerebrovascular Disorders/complications/*genetics | 2 | 66.0 |
Cognition Disorders/complications/*genetics | 2 | 100.0 |
Dementia/complications/*genetics | 2 | 40.0 |
Lovastatin/analogs & derivatives/pharmacology | 2 | 40.0 |
Neurons/cytology/drug effects/*metabolism | 2 | 5.0 |
Poland/epidemiology | 2 | 3.0 |
Nephrotic Syndrome/*genetics | 2 | 15.0 |
Lipoproteins, LDL Cholesterol/metabolism | 3 | 8.0 |
Apolipoproteins A/genetics | 4 | 25.0 |
Antibody Specificity | 6 | 0.0 |
Apolipoproteins A/pharmacology | 3 | 100.0 |
Microtubules/drug effects/*metabolism | 2 | 11.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Recombinant Proteins/antagonists & inhibitors | 2 | 4.0 |
Apolipoproteins E/biosynthesis/*deficiency/*genetics | 2 | 100.0 |
Cell Differentiation/physiology | 2 | 0.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Apolipoproteins E/*biosynthesis/genetics | 9 | 100.0 |
Neurons/*metabolism | 12 | 4.0 |
Alzheimer Disease/*drug therapy/*genetics | 3 | 75.0 |
Cluster Analysis | 4 | 2.0 |
Quebec/epidemiology | 2 | 6.0 |
Alzheimer Disease/cerebrospinal fluid/*genetics | 2 | 66.0 |
Depression/epidemiology | 2 | 28.0 |
Language Tests | 3 | 20.0 |
Attention | 2 | 10.0 |
Models, Animal | 4 | 1.0 |
Neurons/physiology | 2 | 1.0 |
5' Untranslated Regions/genetics | 2 | 1.0 |
Transcription, Genetic/genetics | 3 | 0.0 |
Neuronal Plasticity | 2 | 7.0 |
Apolipoproteins E/chemistry/*physiology | 2 | 100.0 |
Hyperlipoproteinemia/*genetics | 4 | 36.0 |
Endocytosis/*physiology | 5 | 4.0 |
Drug Carriers | 2 | 1.0 |
Liposomes | 6 | 2.0 |
Receptors, LDL/deficiency/genetics/*metabolism | 2 | 100.0 |
Brain Chemistry/physiology | 2 | 7.0 |
Neuraminidase/pharmacology | 2 | 2.0 |
Neuroglia/cytology | 2 | 14.0 |
Precipitin Tests | 13 | 0.0 |
RNA, Messenger/analysis/metabolism | 2 | 1.0 |
Australia | 5 | 2.0 |
Dementia/*genetics/psychology | 2 | 100.0 |
Lipoproteins/blood/chemistry | 3 | 27.0 |
Transgenes/physiology | 2 | 7.0 |
Amyloid/*analysis | 3 | 8.0 |
Alzheimer Disease/classification/*genetics | 2 | 100.0 |
Fetal Blood/metabolism | 2 | 3.0 |
Amyloid beta-Protein/immunology/*metabolism | 2 | 100.0 |
Epitope Mapping | 2 | 0.0 |
Fibroblasts | 3 | 0.0 |
Receptors, Cell Surface/*metabolism | 6 | 1.0 |
*Trinucleotide Repeats | 2 | 1.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Neovascularization, Pathologic/complications | 2 | 66.0 |
*Linkage Disequilibrium | 4 | 2.0 |
Hyperplasia | 2 | 0.0 |
Pharmacogenetics/*methods | 2 | 11.0 |
Brain Injuries/*genetics/*therapy | 2 | 100.0 |
Glasgow Outcome Scale | 4 | 44.0 |
Nigeria | 4 | 6.0 |
Indians, North American/*genetics | 3 | 3.0 |
*Life Style | 3 | 5.0 |
Mexico/epidemiology | 2 | 6.0 |
Cerebral Ventricles/pathology | 3 | 20.0 |
Spain/ethnology | 2 | 6.0 |
*Transcription, Genetic | 2 | 0.0 |
Single-Blind Method | 3 | 1.0 |
Cognition Disorders/diagnosis/*genetics | 2 | 66.0 |
*Genome, Human | 2 | 0.0 |
Lipoprotein Lipase/metabolism | 4 | 3.0 |
Receptors, LDL/*deficiency | 2 | 100.0 |
*Lipoproteins | 2 | 5.0 |
Glycosaminoglycans/metabolism | 2 | 4.0 |
Suramin/pharmacology | 3 | 8.0 |
Binding Sites/physiology | 2 | 1.0 |
Liposomes/metabolism | 3 | 5.0 |
Alzheimer Disease/*genetics/radionuclide imaging | 2 | 100.0 |
Brain/*radionuclide imaging | 3 | 25.0 |
Brain Mapping | 2 | 1.0 |
Fluorodeoxyglucose F18/diagnostic use | 3 | 15.0 |
*Tomography, Emission-Computed | 2 | 4.0 |
Cell Differentiation | 4 | 0.0 |
Apolipoproteins E/biosynthesis/*metabolism/secretion | 2 | 100.0 |
Biological Transport, Active | 2 | 1.0 |
Cell Membrane/*metabolism | 4 | 1.0 |
Culture Media | 7 | 1.0 |
Lysosomes/metabolism | 3 | 2.0 |
Apolipoproteins E/classification/*genetics/metabolism | 2 | 100.0 |
*Genes | 4 | 1.0 |
Mental Status Schedule/statistics & numerical data | 2 | 66.0 |
*Risk Factors | 2 | 18.0 |
Amyloid beta-Protein/isolation & purification/*metabolism | 2 | 100.0 |
Antibodies, Monoclonal | 9 | 0.0 |
Apolipoproteins E/genetics/isolation & purification/*metabolism | 3 | 100.0 |
Epitopes/analysis | 3 | 1.0 |
Endothelium, Vascular/metabolism | 2 | 0.0 |
Extracellular Matrix/metabolism | 2 | 1.0 |
Central Nervous System/cytology/*metabolism | 2 | 22.0 |
Cytoplasm/metabolism | 4 | 0.0 |
Hyperlipidemia/metabolism | 2 | 22.0 |
alpha-Macroglobulins/*analysis | 2 | 9.0 |
Amyloidosis/*metabolism | 3 | 27.0 |
Neurofibrillary Tangles/*metabolism | 3 | 30.0 |
Systole | 2 | 2.0 |
Vasodilation/drug effects | 2 | 3.0 |
Blotting, Southern | 4 | 0.0 |
Alzheimer Disease/*blood/genetics | 2 | 50.0 |
Histocompatibility Antigens Class II/metabolism | 2 | 2.0 |
Aging/*blood | 2 | 2.0 |
North Carolina | 2 | 8.0 |
*African Continental Ancestry Group/genetics | 2 | 16.0 |
Minnesota | 3 | 13.0 |
Parkinson Disease/*genetics/*pathology | 2 | 100.0 |
Cell Movement | 2 | 0.0 |
Alzheimer Disease/etiology/*genetics/metabolism | 3 | 100.0 |
tau Proteins/genetics | 4 | 57.0 |
Ciliary Neurotrophic Factor | 2 | 1.0 |
Reactive Oxygen Species | 2 | 1.0 |
Cholesterol/biosynthesis/*metabolism | 2 | 50.0 |
DNA Fragmentation | 3 | 0.0 |
Neurons/cytology/*drug effects | 2 | 13.0 |
Memory Disorders/pathology | 2 | 100.0 |
Glycosylation End Products, Advanced/*metabolism | 2 | 4.0 |
Neurofibrillary Tangles/metabolism/pathology | 3 | 23.0 |
Supranuclear Palsy, Progressive/metabolism/pathology | 2 | 50.0 |
Brain/*blood supply | 2 | 6.0 |
Alzheimer Disease/*cerebrospinal fluid/genetics/pathology | 2 | 100.0 |
Dementia/etiology/genetics | 2 | 100.0 |
Kidney/chemistry | 2 | 4.0 |
Liver/chemistry | 2 | 2.0 |
Neurodegenerative Diseases/*genetics | 2 | 28.0 |
Biological Markers/cerebrospinal fluid | 3 | 11.0 |
Cyclic AMP/pharmacology | 2 | 1.0 |
Education | 2 | 12.0 |
Psychological Tests | 2 | 5.0 |
Alberta | 2 | 22.0 |
Esterases/genetics | 3 | 16.0 |
Cerebral Infarction/pathology | 2 | 20.0 |
Macaca mulatta | 4 | 0.0 |
Tissue Fixation | 3 | 3.0 |
Lipoproteins, VLDL/*secretion | 2 | 33.0 |
Liver/*secretion | 2 | 25.0 |
Mass Fragmentography | 2 | 0.0 |
Obesity/*physiopathology | 2 | 3.0 |
Alzheimer Disease/*physiopathology | 3 | 15.0 |
Antibodies/immunology | 2 | 0.0 |
Alzheimer Disease/blood/genetics | 2 | 66.0 |
Microcirculation | 2 | 0.0 |
Apolipoproteins E/genetics/metabolism/*physiology | 2 | 66.0 |
Phosphopyruvate Hydratase/genetics | 3 | 23.0 |
Periodicity | 2 | 4.0 |
Family | 7 | 1.0 |
Antilipemic Agents/therapeutic use | 3 | 10.0 |
C-Peptide/blood | 2 | 1.0 |
Carrier Proteins/*blood | 2 | 0.0 |
*Postprandial Period | 3 | 10.0 |
Dementia/*epidemiology/genetics | 2 | 100.0 |
Frontal Lobe/metabolism/pathology | 2 | 25.0 |
Microglia/*metabolism | 2 | 11.0 |
Temporal Lobe/metabolism/pathology | 2 | 33.0 |
DNA/chemistry/genetics | 3 | 0.0 |
Immunoassay/*methods | 2 | 2.0 |
Chromatography, Liquid | 2 | 1.0 |
Mice, Inbred ICR | 5 | 2.0 |
Alzheimer Disease/*etiology | 2 | 40.0 |
Dementia/*etiology | 2 | 50.0 |
Clofibrate/pharmacology | 2 | 9.0 |
Geriatric Assessment | 4 | 21.0 |
*Lipoprotein(a) | 2 | 16.0 |
Paraffin Embedding | 4 | 1.0 |
Demography | 5 | 4.0 |
Immunochemistry | 3 | 1.0 |
Brain Chemistry/genetics | 3 | 7.0 |
Receptors, LDL/chemistry/*genetics | 2 | 25.0 |
Neuroglia/*metabolism | 3 | 6.0 |
*Body Constitution | 2 | 7.0 |
Alzheimer Disease/*diagnosis/*genetics/pathology | 3 | 75.0 |
Receptors, LDL/*genetics/metabolism | 3 | 10.0 |
Foam Cells/metabolism | 3 | 23.0 |
Centrifugation, Density Gradient | 6 | 1.0 |
Immunologic Techniques | 2 | 0.0 |
Alzheimer Disease/*complications/*epidemiology/genetics | 2 | 100.0 |
Nitric Oxide/*biosynthesis | 2 | 4.0 |
Schizophrenic Psychology | 2 | 5.0 |
Hyperlipoproteinemia Type III/*genetics | 8 | 100.0 |
Alzheimer Disease/*enzymology/genetics | 2 | 33.0 |
Choline O-Acetyltransferase/*metabolism | 4 | 3.0 |
Consensus Sequence | 3 | 0.0 |
Apolipoproteins E/*analysis/*genetics | 3 | 100.0 |
Leukocytes | 2 | 3.0 |
Registries | 4 | 1.0 |
Twins | 4 | 10.0 |
Apolipoproteins E/analysis/*metabolism | 2 | 100.0 |
Phosphatidylcholines/pharmacology | 2 | 10.0 |
DNA/isolation & purification | 3 | 2.0 |
*Aged | 5 | 12.0 |
Tacrine/*therapeutic use | 4 | 100.0 |
Norway | 2 | 1.0 |
*Twins | 2 | 7.0 |
Ultracentrifugation | 6 | 3.0 |
Continental Population Groups/*genetics | 2 | 4.0 |
Cell Membrane/metabolism | 6 | 0.0 |
Proteoglycans/metabolism | 2 | 2.0 |
Fatty Acids/*pharmacology | 2 | 7.0 |
Molecular Weight | 18 | 0.0 |
Deoxyribonucleases, Type II Site-Specific | 3 | 1.0 |
Antilipemic Agents/*pharmacology | 2 | 5.0 |
*Apolipoproteins E | 4 | 100.0 |
Frontal Lobe/metabolism | 2 | 6.0 |
Temporal Lobe/metabolism | 3 | 18.0 |
Chromatography, Agarose | 2 | 4.0 |
Proteins/*genetics | 2 | 0.0 |
Alzheimer Disease/*drug therapy/metabolism/physiopathology | 2 | 50.0 |
Adsorption | 2 | 1.0 |
Blood Proteins/chemistry | 2 | 9.0 |
Lipids/*chemistry | 2 | 20.0 |
Surface Properties | 2 | 1.0 |
Dimerization | 5 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Dentate Gyrus/metabolism/pathology | 2 | 33.0 |
Alzheimer Disease/*cerebrospinal fluid/*genetics | 2 | 100.0 |
Cytoskeleton/metabolism | 2 | 0.0 |
Amyloid beta-Protein/*chemistry/*metabolism | 2 | 40.0 |
Amyloid beta-Protein/*toxicity | 4 | 36.0 |
Neuroprotective Agents/pharmacology | 2 | 5.0 |
Receptors, LDL/physiology | 5 | 27.0 |
Dementia/genetics | 2 | 33.0 |
*Cell Compartmentation | 2 | 7.0 |
Cholesterol/*pharmacology | 4 | 21.0 |
Psychometrics | 2 | 3.0 |
Space Perception | 2 | 66.0 |
Russia | 2 | 2.0 |
Cholesterol, Dietary/pharmacology | 2 | 22.0 |
Diabetes Mellitus/epidemiology | 2 | 6.0 |
Hypertension/epidemiology | 3 | 7.0 |
Myocardial Infarction/epidemiology/*genetics | 3 | 23.0 |
Insulin/pharmacology | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
*Carrier Proteins | 2 | 0.0 |
*RNA-Binding Proteins | 2 | 0.0 |
Apolipoprotein A-I/*cerebrospinal fluid | 2 | 100.0 |
Phospholipids/cerebrospinal fluid | 3 | 100.0 |
Neurofibrillary Tangles/*metabolism/*pathology | 2 | 100.0 |
Mice, Transgenic/*genetics/*metabolism | 2 | 40.0 |
Thrombin/metabolism | 3 | 2.0 |
Alzheimer Disease/metabolism/*physiopathology | 2 | 50.0 |
Ethics, Medical | 2 | 11.0 |
Dementia/diagnosis/*genetics | 5 | 100.0 |
Dimyristoylphosphatidylcholine/metabolism | 3 | 37.0 |
Guanidine/pharmacology | 2 | 15.0 |
Protein Denaturation | 9 | 3.0 |
Apolipoproteins B/blood/*metabolism | 2 | 14.0 |
Blood Protein Electrophoresis | 2 | 1.0 |
Apolipoproteins B/blood/*genetics | 3 | 9.0 |
Neurofibrillary Tangles/metabolism/*pathology | 2 | 50.0 |
Brain/*metabolism/radionuclide imaging | 3 | 50.0 |
*Gene Dosage | 3 | 3.0 |
Parkinson Disease/*genetics/metabolism | 2 | 100.0 |
Baculoviridae/genetics | 2 | 1.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
Drug Synergism | 3 | 0.0 |
Fetus/cytology | 3 | 4.0 |
Dogs | 5 | 0.0 |
Chromosomes, Human, Pair 21/genetics | 2 | 4.0 |
Recombination, Genetic | 3 | 0.0 |
Alzheimer Disease/*metabolism/*pathology | 5 | 26.0 |
Cell Death | 2 | 0.0 |
Genetic Diseases, Inborn/*genetics | 2 | 3.0 |
Cardiovascular Diseases/genetics | 2 | 7.0 |
New York City/epidemiology | 2 | 5.0 |
Frontal Lobe | 2 | 25.0 |
Apolipoproteins E/chemistry/genetics/*pharmacology | 3 | 100.0 |
Adenoviridae | 3 | 3.0 |
*Evolution | 4 | 2.0 |
Pan troglodytes | 3 | 2.0 |
*Image Processing, Computer-Assisted | 2 | 4.0 |
Blood Proteins/chemistry/metabolism | 2 | 100.0 |
Iodine Radioisotopes/diagnostic use | 6 | 1.0 |
Apolipoproteins E/isolation & purification/*metabolism | 5 | 100.0 |
Lipoprotein Lipase/*metabolism | 6 | 3.0 |
Milk/enzymology | 2 | 8.0 |
Emulsions | 7 | 10.0 |
Liver/cytology/drug effects/*metabolism | 2 | 10.0 |
Down Syndrome/complications/*genetics | 2 | 25.0 |
Morocco | 2 | 12.0 |
Apolipoproteins E/biosynthesis/genetics/*secretion | 2 | 100.0 |
Arginine | 2 | 2.0 |
Cysteine | 2 | 1.0 |
Lipase/*deficiency | 2 | 33.0 |
Lipoprotein Lipase/*deficiency | 2 | 18.0 |
Hyperlipidemia/epidemiology | 3 | 25.0 |
Obesity/*blood/*genetics | 2 | 40.0 |
Fibroblast Growth Factor 2/pharmacology | 2 | 0.0 |
Neurofibrils/pathology | 2 | 16.0 |
Sclerosis | 2 | 3.0 |
Cerebral Amyloid Angiopathy/*genetics/*pathology | 3 | 100.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 2 | 1.0 |
Fluorescence | 2 | 0.0 |
Dimyristoylphosphatidylcholine | 3 | 20.0 |
Electrophoresis | 5 | 1.0 |
Twin Studies | 2 | 11.0 |
Receptors, Lipoprotein/*genetics | 2 | 33.0 |
DNA, Viral/analysis | 2 | 0.0 |
Apolipoproteins E/*biosynthesis/*genetics | 3 | 100.0 |
Brain Chemistry/*genetics/*physiology | 3 | 100.0 |
Nerve Degeneration | 3 | 4.0 |
Nervous System Diseases/*genetics/pathology | 4 | 100.0 |
Platelet Aggregation/*drug effects | 3 | 2.0 |
Rats, Inbred Strains | 7 | 0.0 |
Alzheimer Disease/complications/*genetics/*psychology | 2 | 100.0 |
Cognition Disorders/diagnosis/genetics | 3 | 100.0 |
Colorado | 3 | 20.0 |
Hispanic Americans | 3 | 4.0 |
Nerve Degeneration/*physiology | 2 | 20.0 |
Skinfold Thickness | 2 | 2.0 |
Apolipoproteins B/*analysis | 3 | 11.0 |
Homocysteine/*blood | 2 | 0.0 |
Apolipoprotein A-I/*metabolism | 3 | 6.0 |
Peptides/chemistry | 2 | 0.0 |
Brefeldin A | 2 | 4.0 |
Cyclopentanes/pharmacology | 2 | 4.0 |
Monensin/pharmacology | 2 | 3.0 |
Genes | 3 | 1.0 |
Down Syndrome/*metabolism | 2 | 9.0 |
Alzheimer Disease/*etiology/genetics/metabolism | 2 | 100.0 |
Greenland | 2 | 22.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Amyloid beta-Protein/*analysis | 5 | 45.0 |
Anthropometry | 4 | 1.0 |
Congo Red | 3 | 20.0 |
Amyloid beta-Protein Precursor/analysis | 2 | 50.0 |
Ubiquitins/analysis | 2 | 22.0 |
alpha 1-Antichymotrypsin/analysis | 2 | 14.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
Fertility/*genetics | 2 | 12.0 |
Bile Acids and Salts/metabolism | 3 | 8.0 |
Sterol O-Acyltransferase/metabolism | 3 | 15.0 |
Chylomicrons/*metabolism | 7 | 21.0 |
Lipolysis/*drug effects | 2 | 6.0 |
Triolein/metabolism | 2 | 20.0 |
Apolipoproteins E/*biosynthesis/genetics/secretion | 3 | 100.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Recombinant Proteins/isolation & purification/metabolism | 3 | 2.0 |
Data Collection | 3 | 3.0 |
Skin/metabolism | 7 | 3.0 |
tau Proteins/cerebrospinal fluid | 5 | 83.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Liver Neoplasms | 4 | 1.0 |
RNA/genetics | 3 | 2.0 |
Regional Blood Flow | 2 | 1.0 |
Sweden | 4 | 1.0 |
Cell Division/physiology | 2 | 0.0 |
Epithelial Cells | 2 | 0.0 |
Receptors, LDL/*drug effects | 2 | 100.0 |
Atrophy/genetics/pathology | 2 | 100.0 |
Magnetic Resonance Imaging/methods | 3 | 3.0 |
Lipoproteins, LDL/blood/*genetics | 2 | 33.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Apolipoprotein A-I/genetics/*metabolism | 2 | 25.0 |
Adenosine Diphosphate/*pharmacology | 2 | 10.0 |
Blood Platelets/drug effects/*metabolism | 2 | 2.0 |
Cell Membrane/drug effects/*metabolism | 2 | 13.0 |
Platelet Aggregation Inhibitors/*pharmacology | 2 | 3.0 |
Synapses | 2 | 25.0 |
Genome, Human | 3 | 0.0 |
*Lewy Bodies | 2 | 100.0 |
Cerebral Cortex/*pathology | 2 | 6.0 |
Immunoassay | 4 | 1.0 |
Cross-Linking Reagents | 3 | 0.0 |
Hypercholesterolemia, Familial/blood/*genetics | 3 | 30.0 |
Socioeconomic Factors | 3 | 1.0 |
Alzheimer Disease/complications/*genetics | 3 | 75.0 |
Amyloid/genetics/metabolism | 2 | 66.0 |
Glycoproteins/*metabolism | 3 | 1.0 |
Genes, Structural | 6 | 0.0 |
Lipase/metabolism | 2 | 3.0 |
Acetylation | 2 | 0.0 |
Hypercholesterolemia, Familial/blood | 2 | 12.0 |
Hyperlipoproteinemia Type III/blood | 2 | 40.0 |
Hyperlipoproteinemia Type IV/blood | 2 | 20.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 25.0 |
*Intestinal Absorption | 3 | 8.0 |
Acetylcholinesterase/*cerebrospinal fluid | 2 | 7.0 |
Hypercholesterolemia/*genetics | 2 | 11.0 |
Liver/*drug effects/metabolism | 2 | 4.0 |
Apolipoproteins E/*immunology | 3 | 75.0 |
Apolipoproteins A/*blood | 2 | 4.0 |
Apolipoproteins E/biosynthesis/*genetics | 4 | 80.0 |
Cercopithecus aethiops | 2 | 0.0 |
Liver/cytology/*metabolism | 3 | 4.0 |
Frontal Lobe/*metabolism | 3 | 33.0 |
T-Lymphocytes/drug effects/immunology | 2 | 2.0 |
Cyanogen Bromide | 2 | 3.0 |
Recombinant Proteins | 4 | 0.0 |
Singapore | 2 | 4.0 |
Glial Fibrillary Acidic Protein/genetics | 3 | 11.0 |
Aging/genetics/metabolism | 3 | 20.0 |
Histocompatibility Antigens Class I/*genetics | 2 | 0.0 |
Gene Therapy/methods | 3 | 3.0 |
Texas | 2 | 5.0 |
*Chromosome Mapping | 8 | 0.0 |
Cosmids | 2 | 0.0 |
Immune Sera | 2 | 0.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Staining and Labeling | 3 | 0.0 |
Molecular Probes/genetics | 3 | 3.0 |
Oligonucleotide Probes | 2 | 0.0 |
Great Britain | 2 | 0.0 |
Premenopause | 2 | 2.0 |
Larva | 2 | 6.0 |
Apolipoproteins E/blood/*cerebrospinal fluid/*genetics | 2 | 100.0 |
Apolipoproteins E/*biosynthesis/blood | 2 | 100.0 |
Horses | 2 | 1.0 |
Alzheimer Disease/diagnosis/genetics | 3 | 100.0 |
Carrier Proteins/*genetics/metabolism | 3 | 1.0 |
Hyperlipoproteinemia/blood/*etiology | 2 | 100.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
*Apolipoproteins E/genetics/metabolism | 2 | 100.0 |
DNA | 3 | 0.0 |
Infant, Newborn/*blood | 2 | 4.0 |
Lipoproteins, HDL/*blood | 8 | 4.0 |
Neurofibrillary Tangles | 2 | 28.0 |
Hyperlipoproteinemia Type III/blood/*genetics | 8 | 88.0 |
Triiodothyronine/*pharmacology | 2 | 4.0 |
Muscle, Smooth/cytology/metabolism | 2 | 18.0 |
Lipoproteins/blood/*chemistry | 2 | 33.0 |
Serum Albumin/*metabolism | 2 | 4.0 |
Arteriosclerosis/blood/etiology | 2 | 14.0 |
Lipoproteins, HDL/*chemistry | 2 | 11.0 |
New York City | 2 | 6.0 |
Aorta | 2 | 1.0 |
Recombinant Fusion Proteins/pharmacology | 2 | 2.0 |
Diagnostic and Statistical Manual of Mental Disorders | 2 | 8.0 |
Iron/metabolism | 2 | 1.0 |
Estrogens/*pharmacology | 2 | 2.0 |
Fatty Acids, Nonesterified/metabolism | 2 | 6.0 |
Leukocytes/metabolism | 2 | 1.0 |
Apolipoprotein A-I/*analysis | 2 | 18.0 |
Liver Neoplasms, Experimental | 3 | 6.0 |
Chylomicrons/blood/metabolism | 2 | 66.0 |
Chemical Fractionation | 2 | 2.0 |
Hypercholesterolemia/*blood | 2 | 9.0 |
Immunoelectrophoresis | 3 | 1.0 |
Hybrid Cells | 4 | 0.0 |
Glycosides/metabolism | 2 | 50.0 |
Gene Amplification | 3 | 0.0 |
Malaysia/ethnology | 2 | 15.0 |
Hypercholesterolemia/blood | 2 | 10.0 |
Chromatography | 2 | 1.0 |
Enzyme Activation | 2 | 0.0 |
Nucleic Acid Denaturation | 3 | 3.0 |
Golgi Apparatus/drug effects/*metabolism | 2 | 28.0 |
Cholesterol/*physiology | 2 | 18.0 |
Environment | 2 | 2.0 |
Recombinant Proteins/genetics/isolation & purification/metabolism | 2 | 2.0 |
Parity | 2 | 1.0 |
Swine/*genetics | 2 | 1.0 |
Rural Health | 2 | 11.0 |
Molecular Conformation | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Fatty Acids/blood | 2 | 4.0 |
Apolipoproteins A/metabolism | 2 | 11.0 |
Photochemistry | 2 | 3.0 |
Feces/chemistry | 2 | 4.0 |
Blood | 3 | 1.0 |
Astrocytoma/*metabolism | 2 | 8.0 |
Interleukin-1/genetics | 2 | 2.0 |
Macrophage Activation | 2 | 1.0 |
Platelet-Derived Growth Factor/genetics | 2 | 6.0 |
Lipoproteins, HDL/*physiology | 2 | 20.0 |
Chickens | 3 | 0.0 |
*Eggs | 2 | 66.0 |
Phosphatidylcholines/metabolism | 4 | 4.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Coronary Disease/epidemiology | 3 | 15.0 |
Thrombin/pharmacology | 2 | 0.0 |
Protein Kinases/metabolism | 2 | 0.0 |
*Apoptosis | 2 | 0.0 |
Cholesterol/analysis | 5 | 10.0 |
Immunodiffusion | 3 | 1.0 |
Methionine/chemistry | 2 | 14.0 |
Hyperlipoproteinemia/blood | 2 | 25.0 |
Cholesterol Esters/*biosynthesis | 2 | 25.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Aging/*pathology | 2 | 7.0 |
Apolipoproteins C/*pharmacology | 2 | 40.0 |
Tumor Necrosis Factor-alpha/*genetics | 4 | 1.0 |
LDL-Receptor Related Protein 1/*metabolism | 3 | 33.0 |
Apolipoprotein A-I | 8 | 7.0 |
Apolipoproteins A/analysis | 2 | 33.0 |
Nerve Growth Factors/cerebrospinal fluid | 3 | 42.0 |
S100 Proteins/cerebrospinal fluid | 3 | 33.0 |
Subarachnoid Hemorrhage/*cerebrospinal fluid | 2 | 66.0 |
Receptors, Lipoprotein | 2 | 20.0 |
RNA, Messenger/genetics/isolation & purification | 2 | 3.0 |
Acute-Phase Reaction/*blood | 2 | 7.0 |
Brain Injuries/*cerebrospinal fluid | 2 | 40.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Glucose-6-Phosphate Isomerase/genetics | 2 | 18.0 |
Lipoproteins/genetics | 2 | 25.0 |
Lipoproteins, VLDL/blood/isolation & purification | 2 | 33.0 |
Cysteamine | 2 | 100.0 |
Myotonic Dystrophy/*genetics | 2 | 3.0 |
Apolipoproteins E/*blood/isolation & purification | 3 | 75.0 |
Apolipoprotein A-II | 3 | 6.0 |
Hela Cells/metabolism | 2 | 1.0 |
Plasmids | 5 | 0.0 |
Bone Marrow Cells | 2 | 0.0 |
Diabetes Mellitus/genetics | 2 | 5.0 |
Insulysin/*genetics | 2 | 25.0 |
Dementia, Vascular/diagnosis/*genetics | 2 | 66.0 |
Brain Ischemia/*complications | 2 | 33.0 |
Lipoproteins, VLDL/analysis | 3 | 27.0 |
Biological Markers/analysis | 4 | 0.0 |
DNA Restriction Enzymes | 5 | 1.0 |
*Deoxyribonucleases, Type II Site-Specific | 2 | 3.0 |
Lipoproteins, HDL/analysis | 2 | 22.0 |
Apolipoprotein A-I/cerebrospinal fluid | 2 | 100.0 |
Cholesterol/cerebrospinal fluid | 2 | 100.0 |
Utah | 2 | 7.0 |
Apolipoproteins E/cerebrospinal fluid | 2 | 100.0 |
Cerebrospinal Fluid Proteins/analysis | 3 | 12.0 |
Apolipoproteins/*analysis/genetics | 2 | 50.0 |
DNA Restriction Enzymes/metabolism | 2 | 2.0 |
Cardiovascular Diseases/epidemiology | 2 | 7.0 |
Densitometry, X-Ray | 2 | 1.0 |
3' Untranslated Regions/genetics | 3 | 3.0 |
Hyperlipidemia/*genetics | 2 | 9.0 |
Lipoproteins/blood/*pharmacology | 2 | 50.0 |
Apolipoproteins E/*genetics/isolation & purification | 2 | 66.0 |
Lipid Bilayers | 2 | 4.0 |
*Chromosomes, Human, 19-20 | 7 | 31.0 |
Complement 3/*genetics | 2 | 3.0 |
DNA Restriction Enzymes/diagnostic use | 3 | 8.0 |
Intelligence Tests | 2 | 3.0 |
Israel | 2 | 1.0 |
Perfusion | 3 | 1.0 |
Bile Acids and Salts/analysis | 2 | 33.0 |
*Cloning, Molecular | 2 | 0.0 |
DNA/*isolation & purification | 2 | 5.0 |
Fetal Blood/*analysis | 2 | 5.0 |
Alzheimer Disease/*genetics/immunology | 2 | 50.0 |
Lipoproteins, VLDL/*genetics | 2 | 66.0 |
*Apolipoproteins C | 2 | 12.0 |
*Phospholipid Transfer Proteins | 2 | 1.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Hyperlipoproteinemia Type III/*metabolism | 2 | 100.0 |
Kidney/metabolism | 2 | 0.0 |
Apolipoproteins C/metabolism/pharmacology | 2 | 66.0 |
Alzheimer Disease/enzymology/*genetics/physiopathology | 2 | 100.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Hypolipoproteinemia/*blood | 2 | 9.0 |
Alzheimer Disease/*metabolism/physiopathology | 2 | 66.0 |
Brain/*metabolism/pathology/physiopathology | 2 | 10.0 |
Urban Health | 2 | 5.0 |
3' Untranslated Regions/*genetics | 2 | 5.0 |
Testosterone/*blood | 2 | 0.0 |
Amine Oxidoreductases/genetics | 2 | 1.0 |
Dementia, Vascular/genetics | 2 | 50.0 |
Dementia, Vascular/*genetics/psychology | 2 | 100.0 |
